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ABSTRACT 
This project aimed to clinically and biochemically characterise a novel phenotype 
which we have named Robinow Syndrome – Osteosclerotic type (RS-OS). 
Robinow Syndrome (RS) is a rare form of mesomelic dwarfism defined by a 
distinctive facial gestalt known as “fetal facies” – a combination of features 
including hypertelorism and midface hypoplasia. RS can be caused by loss-of-
function mutations in genes encoding components of planar cell polarity WNT 
signalling. Osteosclerosis is associated with gain-of-function mutations in 
mediators of a different aspect of WNT signalling, the canonical WNT pathway.  
This thesis details three sporadic cases of RS-OS. Before this project began a 
combination of next generation and Sanger sequencing identified that two of 
these individuals had similar heterozygous de novo mutations in gene for the 
pan-WNT component DVL1, which has not previously been associated with RS. A 
third case was identified during this project and Sanger sequencing revealed 
another, similar, de novo mutation in DVL1. All three DVL1 mutations fall within 
the 14th exon and cause a -1 frameshift which predicts a DVL1 product with the 
wild type C-terminal sequence replaced by a novel amino acid sequence, which is 
shared across all three affected individuals. We hypothesised that these DVL1 
mutations cause osteosclerosis through a gain-of-function leading to an increase 
in canonical WNT signalling. 
Transcript from cell lysates of cultured dermal fibroblasts taken from an affected 
individual were analysed by Sanger sequencing and restriction enzyme digest 
revealed that the mutation-bearing mRNA was endogenously expressed. 
Transient transfection of mouse C2C12 cells with EGFP-tagged DVL1 constructs 
showed similar protein levels between mutant and wild type DVL1 with 
fluorescent Western blotting. Taken together these experiments showed that the 
mutant allele is endogenously transcribed as a persistent mRNA, and that the 
majority of the protein product of that transcript is stable. 
Canonical WNT signalling was studied with a transient transfection-based 
TOPFlash assay. These revealed that, paradoxical to the osteosclerotic 
phenotype, the mutant DVL1 was significantly less active in the canonical WNT 
pathway than wild type DVL1. However the co-expression of the mutant DVL1 
alongside the wild type DVL1 lead to a significant (~3-fold, P < 0.01) increase in 
canonical WNT activity over the same amount of wild type DVL1 expressed 
alone. This co-expression may explain the clinical osteosclerosis: the affected 
individuals are heterozygous for the DVL1 mutations thus are likely to co-
express mutant and wild type DVL1. 
This work establishes that novel mutations in DVL1, a gene previously not 
associated with RS, causes an osteosclerotic form of RS. These mutations are 
likely to lead to osteosclerosis through a gain-of-function mechanism, with an 
increase in canonical WNT signalling. However this gain-of-function, in vitro, 
depends upon the presence of wild type DVL1 alongside the mutant DVL1. This 
wild type-dependent gain-of-function is, to our knowledge, unique amongst 
Mendelian disorders. 
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1. CHAPTER ONE - INTRODUCTION 
  
   2 
1.1. Overview of thesis structure 
This project largely took place within the laboratory, however there was a strong 
clinical element to the work shown here.  
The Introduction will firstly detail Robinow Syndrome (RS), with a particular 
focus on the genetic and skeletal aspects of this disorder as these are directly 
relevant to this thesis. Some forms of RS are caused by loss-of-function 
mutations in WNT signalling mediators, and this work establishes mutations 
affecting a previously unassociated component of the WNT pathways, DVL1 
(Dishevelled-1), as causative of RS. These individuals also show osteosclerosis, 
which is atypical in RS, but reminiscent of the gain-of-function WNT-related 
osteosclerotic phenotypes. It is this osteosclerotic phenotype, due to its possible 
gain-of-function mechanism, that is the focus of this project. The second part of 
the Introduction will review WNT signalling, with a particular focus on its 
involvement in skeletogenesis. The last component of the Introduction is a 
focused overview of DVL1, the gene central to this work. Chapter 2 provides the 
clinical analysis of the three cases. The clinical phenotype is important as it drove 
the hypothesis-based laboratory analysis that is contained in the subsequent 
chapters. Chapter 3-6 contain the laboratory-based work, firstly Methods 
(Chapter 3), then endogenous DVL1 expression (Chapter 4), transfected DVL1 
expression (Chapter 5), and the effect of DVL1 transfection on canonical WNT 
signalling (Chapter 6). The clinical and laboratory results are discussed in 
Chapter 7. 
This work has generated two papers, which have been included in the 
appendices. The first, a clinical description of this RS-OS (Robinow Syndrome – 
   3 
Osteosclerotic type) was published in the first half of the year (in the American 
Journal of Medical Genetics part A, ref. 1)  – some of the research was carried out 
during a Summer Studentship but the work was completed in the course of this 
BMedSc. The second is currently in review at the American Journal of Human 
Genetics and it discusses the nature of the DVL1 mutations in these cases, as well 
as the impact this mutant protein has on the canonical WNT signalling pathway.  
1.2. Value of studying rare syndromes 
The investigation of rare genetic pathologies can illuminate the molecular nature 
of normal physiology and, in future, provide insights into new therapies and 
treatments for common morbidities.  The study of rare Mendelian disorders has 
been revolutionised by next generation sequencing technology, which has 
allowed the efficient identification of the genetic aetiology of rare conditions. In 
turn the identification of the DNA-level aetiology allows focussed functional 
studies at the protein level giving insights into the signalling pathways active 
within a cell. 
Bone biology has particularly benefitted from the study of rare phenotypes.  In 
1955 Van Buchem identified a rare recessive sclerosing bone dysplasia that now 
bears his name  (Van Buchem’s Disease).2 In 2002 a genetic analysis of a family 
with Van Buchem’s disease identified a mutation in the gene, SOST, which 
encodes the protein Sclerostin as causative of this condition.3 The identification 
of this gene was instrumental in future work outlining its function, which is to 
reduce catabolic bone metabolism by inhibiting an aspect of the WNT signalling 
pathway.4,5 The therapeutic implications for an identification of a mediator 
responsible for reducing bone mass are substantial, and currently Sclerostin 
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antibodies (trade named Blosozumab and Romosozumab) are approaching the 
end of clinical trials for their use in osteoporosis. An insight from a rare disorder 
may lead to the treatment of one of the most common and debilitating health 
conditions. 
1.3. The Robinow Syndrome 
Robinow Syndrome is a rare genetic disorder first described by the eponymous 
Robinow in 19696 as a new form of dwarfism. There are just over 100 cases from 
throughout the world of RS reported in the literature. The prevalence is equal 
between the sexes. RS is traditionally characterised by mesomelic dysplasia, 
hypoplastic genitalia, and a characteristic facial gestalt often referred to as “fetal 
facies” (most notably features are hypertelorism, broad mouth, midface 
hypoplasia, and a wide and depressed nasal bridge). Robinow’s initial family 
showed a dominant inheritance pattern, but a recessive variant of RS was 
identified in 1978, and initially termed Covesdem Syndrome.7,8 This recessive RS 
is again characterised by the above findings, but is generally more severe, with 
costovertebral segmentation defects such as rib fusions and hemivertebrae (the 
origin of the original name). Since its identification the recognised clinical 
phenotype of RS has become increasingly diverse, with heart defects, deafness, 
oral abnormalities, developmental delay, and a plethora of other deficits being 
linked to the disorder. The “fetal facies” with the marked hypertelorism is the 
clearest diagnostic feature of RS, with other defects occurring with varying 
severity (see ref. 9 for a comprehensive review of the findings of RS, the common 
signs are presented in Table 1.1 modified and reproduced with permission from 
the same ref.). 
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Table 1.1. Features of Robinow Syndrome.  
The table shows the frequencies of the common features of dominant and recessive RS. It 
is reproduced, with permission, from ref. 9. The table has been modified to exclude 
features with frequencies of less than 50% in both forms. 
 
Characteristic 
Prevalence in Dominant RS 
(%) 
Prevalence in Recessive RS 
(%) 
Hypertelorism 100 100 
Anteverted mares 96 96 
Wide nasal bridge 97 95 
Micropenis 84 100 
Upturned nose 87 97 
Mesomelic limb shortening 80 100 
Short stature 81 97 
Midface hypoplasia 81 94 
Short nose 81 93 
Brachydactyly 81 91 
Down-slanted mouth corners 63 95 
Clinodactyly 70 88 
Prominent forehead 79 77 
Triangular mouth 65 86 
Short hands 62 84 
Dental malocclusion 49 94 
Cryptorchidism 72 67 
Hypoplastic labia minora 50 81 
Depressed nasal bridge 78 49 
Hypoplastic clitoris 46 80 
Micrognathia 57 68 
Hemivertebrae 23 98 
Long eyelashes 54 59 
Gum hyperplasia 36 71 
Long philtrum 65 39 
Bifid tongue 39 59 
Scoliosis 18 77 
Macrocephaly 64 26 
Highly arched palate 52 14 
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1.3.1. Robinow Syndrome and skeletal patterning 
RS was initially classified as a mesomelic form of dwarfism, however in dominant 
RS mesomelia is not always present.10 Recessive RS shows a far greater degree of 
patterning abnormality, with segmental defects such as rib fusions and 
hemivertebrae rarely observed in dominant RS.9 Brachydactyly, notably with 
hypoplasia of the distal phalanx of the hands and feet, with a bifid thumb and 
great toe, is a common feature of RS.11  
1.3.2. Robinow Syndrome and osteosclerosis  
RS, as previously discussed, is a heterogeneous disorder with a great variety of 
features associated with it, however, there are only two previous reports of 
osteosclerosis. One reports a father-to-son transmission of RS where the father 
has generalised osteosclerosis and the infant son does not.12 The second is a 
sporadic case with osteosclerosis of the mastoids.13 None of these individuals 
have segmentation defects, and, when the inheritance pattern is also considered 
(vertical transmission and sporadic), it is likely that these cases are of dominant 
RS. These cases are discussed in more detail in Chapter 2.  
1.3.3. Genetics of Robinow Syndrome 
As well as the clinical diversity RS is also genetically heterogeneous. Recessive 
RS has been genetically defined by mutations in the gene encoding the orphan 
tyrosine kinase receptor, ROR2.14,15 The mutations in ROR2 are biochemically 
interesting as another disorder, the dominant brachydactyly type B, is caused by 
a different set of ROR2 mutations.16 The mutations that cause BDB are all 
truncating, affect the intracellular domain of ROR216,17 and are predicted to lead 
to a dominant negative gain-of-function. In contrast those in recessive RS are 
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more likely to act through a loss-of-function (a review comparing the mutations 
in these two disorders is available at ref. 18). Mechanistically it has been shown 
that recessive RS causing variants lead to a protein that accumulates and is 
degraded in the endoplasmic reticulum, making the mutations null alleles.19 
Mutations in WNT5A, which encodes the typical binding partner of ROR2, are 
found in some individuals with dominant RS, but these are not present in all 
cases.20 There are no other genes previously associated with RS, but our work 
has established an additional gene, DVL1, which is associated with a distinct sub-
phenotype of dominant RS. Critically ROR2, WNT5A, and DVL1 are all mediators 
of the WNT signalling pathways (discussed in section 1.4), so while the defects 
show locus heterogeneity they are linked functionally through a common 
pathway. 
1.3.4. Mouse models of Robinow Syndrome 
There are three mouse models of human Robinow Syndrome. As in humans 
homozygous knockout of Ror2 leads to a RS phenotype in mice,21 as does a 
homozygous knockout of Wnt5a.20,22 Additionally null and hypomorphic alleles 
of Prickle1 (a component of the WNT signalling cascade) lead to an RS phenotype 
in mice,23 but defects in human homologue, PRICKLE1, have not been identified 
in human RS. PRICKLE1 variants are, however, associated with human cleft 
palate,24 a dysmorphic feature that occurs in RS. 
While mice are not used within this work there are a number of reasons why 
these models are relevant. Firstly the mouse models deepen the understanding 
of the pathway responsible for RS. For example the Prickle1 knockouts provide 
evidence for the potential role of Prickle1 in RS. Secondly the observation that 
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mice will phenocopy RS adds confidence to subsequent discussion surrounding 
the non-RS phenotype of homozygous knockouts of Dvl1 in mice.25 
1.4.  WNT signalling pathways 
WNTs are a diverse family of lipophilic cysteine rich extra-cellular signalling 
molecules, which give rise to numerous intracellular responses. WNT signalling 
regulates a great range of processes including, but by no means limited to, 
skeletal patterning, bone mass, and mechanosensing.  WNTs are often 
considered ‘morphogens’ – long-range signals that act in a concentration 
dependent manner, and they are of particular importance during development. 
WNTs are produced and expressed ubiquitously during development and 
throughout an organism’s life (WNT signalling is reviewed in refs. 26, 27, and 
28). 
The name ‘WNT’ is derived from a contraction of Wingless and Insertion, 
documenting the history of its discovery.29 Broadly there are three intracellular 
WNT signalling pathways: the canonical/β-catenin dependent pathway, and the 
non-canonical pathways, further divided into the WNT/Ca2+ and WNT/PCP 
signalling pathways. This chapter will discuss the basic mechanisms and effects 
of these pathways in bone with a particular focus on DVL1. At the end of this 
section Figure 1.1 presents an overview of WNT signalling. 
1.4.1. WNT agonists and antagonists 
There are 19 extracellular WNTs (the classical WNT ligand) in humans. Dividing 
these ligands into canonical and non-canonical agonists is difficult as the nature 
of the receptors expressed on the responding cell influence the downstream 
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signals triggered by any given WNT.30 However in normal physiological 
conditions WNT1, WNT3A, and WNT8 can be considered canonical WNT 
agonists, where as WNT5A and WNT11 preferentially mediate non-canonical 
activation (reviewed in ref. 27). 
There are now known to be other, non-WNT, extracellular proteins that also 
activate the WNT pathway including Norrin31 and proteins in the R-spondin 
family.32 Both of these activate the β-catenin pathway. For clarity this chapter 
will refer simply to WNT agonists as “WNTs” as this work does not differentiate 
between canonical WNT agonists. 
There are a number of WNT antagonists but only a few are relevant to this work. 
Firstly the non-canonical WNT pathways will inhibit the β-catenin dependent 
pathway. The precise mechanism of this is unclear but it occurs downstream of 
canonical β-catenin stabilisation30 (pictured in Figure 1.1 as a dotted line). 
Secondly the gene SOST (discussed previously) encodes the extracellular protein 
Sclerostin that will inhibit canonical WNT signalling via an interaction with the 
Lipoprotein Related Peptides (LRPs).5 
1.4.2. Canonical/β-catenin WNT pathway 
This was the first WNT pathway identified and it remains the best understood. 
An interaction between a WNT, the Frizzled (Fz) receptor, and an LRP co-
receptor initiates the molecular cascade culminating in β-catenin accumulation 
and translocation to the nucleus which activates transcription factors, most 
notably T cell factor (TCF) and lymphoid enhancer-binding factor (LEF). The 
WNT/Fz/LRP complex interacts with DVL and Axin. Axin in turn acts as a 
scaffold directly binding to DVL, Caseine Kinase 1 (CK1), Glycogen Synthase 
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Kinase 3 (GSK3), and APC (adenomatous polyposis coli). Unbound CK1, GSK3, 
and APC form a destruction complex which phosphorylates β-catenin, in turn 
promoting its ubiquitination and degradation. The WNT mediated interaction of 
this complex with Axin de-activates the destruction complex. Thus, in the 
presence of WNT, cytoplasmic β-catenin accumulates and subsequently 
translocates to the nucleus where it interacts with the aforementioned 
transcription factors (see ref 26 for a detailed review). 
DVL polymerisation is an important step in canonical signalling. It is well 
documented that DVL will form cytoplasmic puncta, which have been shown not 
to be associated with vesicles, being instead polymers of DVL.33 The formation of 
these dynamic DVL polymers acts as an unusual regulatory mechanism. The local 
accumulation of DVL, driven by the formation of polymers, facilitates canonical 
WNT signalling by concentrating DVL sites which then interact with downstream 
WNT mediators.34 There is evidence that DVL also plays a role within the nucleus 
in canonical WNT signalling. The disruption of the nuclear import signal in dsh 
(fly DVL) abrogates its ability to signal in the canonical WNT pathway in 
transfected mammalian cells.35 
1.4.3. PCP/WNT signalling 
This aspect of WNT signalling is primarily considered to control the convergent 
extension movements of gastrulation during embryogenesis.27 The pathway is 
similar to the Planar Cell Polarity (PCP) pathway in Drosophila (reviewed in ref. 
36), hence the name. There is some debate regarding which aspects of WNT 
signalling are encompassed by PCP/WNT but this work will use the term PCP to 
describe the non-β-catenin, non-Ca2+ mediated aspects of WNT signalling. 
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WNT5A is the archetypal activator of non-canonical WNT signalling. A 
phenotypic similarity between WNT5A-/- mice and knockouts of the Orphan 
Tyrosine Kinase Receptor 2 (ROR2-/-) mice led to the identification of the 
transmembrane ROR2 as a receptor for WNT5A. ROR2 will associate with the 
traditionally non-canonical Fz receptors Fz2 and Fz5, to act as a WNT co-
receptor.30  
PCP signalling begins with an interaction between WNT5A and ROR2 either 
acting alone or as a co-receptor with an appropriate Fz. This initial interaction 
leads to the polarisation of a Fz-DVL-Diversin proximal to the signal and Prickle-
Vangl distally, thus establishing a polarity across the axis of the cell (discussed in 
refs. 37 and in 38).  
DVL, subsequent to this polarisation, interacts with a GTP-binding protein, RhoA, 
via DAAM1.39 Work in Drosophila showed that the DVL-activated GTP-bound 
RhoA will interact with Drok (ROCK in humans) which affects actin 
polymerisation via the non-muscle myosin regulatory light chain 
phosphorylation of myosin II.40 
DVL will also activate another small GTP-binding protein, Rac, which will in turn 
activate c-Jun N-terminal kinase (JNK), which influences the actin cytoskeleton 
and gene transcription. The mechanism for this DVL-Rac interaction is still 
unknown.41 There is some debate as to whether this part of PCP signalling 
should be grouped with WNT5A/ROR2 signalling, as ROR2 may not be required 
to activate JNK nor to inhibit β-catenin signalling.42 
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As discussed above non-canonical WNT signalling inhibits canonical WNT 
signalling through an unknown mechanism downstream of the β-catenin 
stabilisation30 (this thesis has grouped this action with the PCP/WNT pathway). 
Interestingly, as PCP/WNT is based on the establishment of polarity, both over 
and under expression of PCP/WNT components can lead to the same 
phenotype.43 This is an indication that some PCP/WNT mutations may be better 
considered as ‘disruptive to’ PCP/WNT signalling rather than the simple binary 
notion of a loss- or gain-of-function. 
1.4.4. Calcium signalling and DVL 
Initial over expression experiments in zebrafish blastulae showed that WNT5A or 
Fz2 increased the frequency of calcium influxes.44,45 The WNT-Fz interaction 
activates heterotrimeric G-proteins which in turn activate phospholipase C. This 
stimulates inositol-1,4,5-trisphosphate production, which triggers the release of 
Ca2+ from intracellular stores. The role and mechanisms of the Ca2+/WNT 
pathway is reviewed more comprehensively in ref. 46. 
The precise role of DVL in this Ca2+ response is very complex. Early work showed 
that over-expressing a DVL construct that lacked a specific domain called DIX 
(discussed in a section 1.5.2) would lead to a pertussis toxin insensitive (i.e. not 
G-protein dependent) increase in the frequency of Ca2+ influxes. In contrast over-
expressing full length DVL led to a milder increase in Ca2+ influxes.47 The 
insensitivity to pertussis toxin led the authors to conclude that either DVL was 
acting downstream or in parallel to the G-protein mediated response. A more 
recent study used fluorescently tagged constructs and live cell imaging to 
observe the DVL-Fz-G-protein interactions in real time. This work argued for a 
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complex of all three molecules in the initiation of the Ca2+ response. DVL, in this 
complex, had an enigmatic regulatory function where both its over- and under-
expression would interfere with the complex formation and abrogate the WNT 
induced Ca2+ response.48 The DIX domain was identified as inhibiting the Fz-G-
protein association,48 which is consistent with the findings discussed above.47 
Taken together these results may indicate that DVL has dual roles: both 
regulating the Fz-G-protein mediated calcium signalling, and promoting calcium 
signalling either down stream or in parallel to G-proteins (shown with a dotted 
line in Figure 1.1). 
1.4.5. WNT signalling in bone metabolism and skeletal disease 
The role of WNT signalling in bone metabolism is well established (see 49 for a 
comprehensive review). In broad terms the canonical pathway is associated with 
regulation of bone mass, the PCP pathway with skeletal patterning, and the 
calcium dependent signalling is involved in some aspects of mechanosensing. 
The canonical WNT pathway is strongly associated with the regulation of bone 
mass. Mutations in SOST, the secreted WNT antagonist, will cause Van Buchem’s 
and Sclerostosis – conditions of markedly increased bone mass.3,50 Gain-of-
function mutations in LRP5, an activator of canonical signalling, will also cause a 
high bone mass phenotype.51 Conversely both heterozygous and homozygous 
loss-of-function mutations in LRP5 will cause osteoporosis.52,53,54 Additionally an 
LRP4 haplotype has been associated with low bone mineral density in genome-
wide association studies55 and mouse knockouts of genes encoding the canonical 
agonists WNT3A, LRP4, 5, and 6 are associated with low bone mass (reviewed in 
49). 
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The PCP/WNT pathway mediates skeletal patterning rather than bone mineral 
accrual. Loss-of-function mutations in the PCP/WNT components WNT5A and 
ROR2 will cause dominant and recessive RS respectively.14,15,20 Different 
mutations in ROR2 cause the severe brachydactylic type B, another skeletal 
patterning defect.16 Prickle1, a PCP mediator, will cause an RS phenotype in mice 
when knocked out23 and common and rare variants in PRICKLE1 are associated 
with cleft palate in humans.24 Interestingly WNT5A knockdown is also associated 
with a low bone mass phenotype in mice through an impact on 
osteoblastogenesis, as WNT5A potentiates osteoblastogenesis over adipogenesis 
in differentiating mesenchymal stem cells.56 As discussed in section 1.4 
PCP/WNT regulates convergent-extension movements in embryogenesis, 
therefore defects in PCP/WNT components cause convergent-extension 
dependent phenotypes in humans: such as the aforementioned cleft palate and 
neural tube defects. A number of variants in PCP/WNT mediators have been 
found to associate with neural tube defects in humans, these include, amongst 
others: VANGL157 and 2;58 PRICKLE1;59 FRIZZLED6;60 and DVL261 (these are 
reviewed in ref. 62). 
The role of the WNT/Ca2+ in bone is less well defined, but it is involved in the 
remodelling associated with mechanical stress, effecting both osteoblasts and 
osteoclasts.63,64 
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Figure 1.1. An overview of WNT signalling  
Note the three WNT cascades, which are, from left to 
right: the canonical/β-catenin, the PCP/WNT, and the 
Ca2+/WNT pathways. DVL is marked in red.  In response 
to WNT stimulus, in the canonical cascade, the DVL 
dynamic DVL polymer interacts with the β-catenin 
destruction complex, which stops phosphorylating β-
catenin. β-catenin, when unphosphorylated, is not 
ubiquitinated and degraded, thus it accumulates within 
the cytoplasm and translocates to the nucleus where it 
alters gene transcript through interactions with 
transcription factors (notably LEF and TCF) and DVL. In 
the PCP pathway WNT stimulus acts via ROR2/Fz to 
cause DVL and Diversin to polarize to the proximal pole 
of the cell and Prickle and Vangl to move to the distal 
pole. DVL then interacts with Rac and RhoA which 
activate JNK and ROCK respectively. Both ROCK and JNK 
influence the actin cytoskeleton and JNK also alters gene 
transcription. The mechanism by which the PCP inhibits 
the canonical pathway is unknown. In the Ca2+/WNT DVL 
acts in parallel to and directly with a G-protein initiated 
cascade that culminates in an increase in the 
intracellular calcium levels. This figure was drawn on the 
basis of the references contained in section 1.4.  
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1.5. Dishevelled 
Dishevelled was originally identified in Drosophila (in which it is know as dsh) 
and its name derives from the disruption in bristle and hair polarity caused by its 
mutation.65 Drosophila has one isoform of Dishevelled, whereas mammals have 
three (DVL1, 2, and 3 in humans), however the basic structure of each DVL is 
strongly conserved across the paralogues and they all show a close resemblance 
to fly dsh.66 As discussed previously DVLs are WNT mediators that act across all 
known WNT pathways (see Figure 1.1). Often they are described as “scaffold-
like” proteins, acting directly downstream of the transmembrane WNT receptor 
(generally a Fz, but sometimes an LRP or ROR2). Most mammalian DVL is DVL2, 
making up over 90% of the cellular DVL.67 However DVL1 and 3 (only ~5% each) 
have a greater impact upon canonical WNT signalling when knocked down than 
DVL2.67 
1.5.1. DVL1 gene structure 
DVL1 is a 15-exon gene located in the short arm of chromosome 1 in humans. 
The top panel of Figure 1.2 shows DVL1 gene structure. The three mutations 
discussed in this thesis occur in the 14th exon. 
1.5.2. Regions of DVL1 protein 
All DVLs have the same three conserved regions, which, from N-terminal to C-
terminal, are: the DIX (Dishevelled, Axin); the PDZ (Postsynaptic density 95, 
Discs Large, Zonula occludens-1); and the DEP (Dishevelled, Agl-10, Pleckstrin). 
In broad terms the DIX domain is important for DVL’s ability to self associate into 
supramolecular complexes (forming visible puncta), the PDZ allows the 
transduction of signals from the intramembrane Frizzled receptor, and the DEP 
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interacts with downstream mediators of WNT signalling  (DVL function is 
reviewed in ref. 37). Between the DIX and PDZ domains is a basic region that is 
believed to be important for the interaction of kinases with DVL. In particular 
PAR1 binds to this region,68 as does Casein Kinase 2.69,70 There is also a proline 
rich region between the PDZ and DEP which contains an SH3-binding domain.71 
This proline rich domain has been shown to bind to Src family tyrosine kinases 
in response to WNT3A stimulus, and the subsequent phosphorylation (driven by 
the activated kinases) is a necessary step for β-catenin nuclear localisation and 
TCF/LEF activation (both measures of canonical WNT activation).72 Of particular 
interest to this project Src tyrosine kinases also bound to the C-terminal of Dvl2 
(residues 511-736), which is broadly homologous to the C-terminal of DVL1.72 
The bottom panel of Figure 1.2 is a cartoon of DVL1 showing the three major 
regions (approximately to scale) and the location of the basic (B) and proline rich 
(P) regions. Note the substantial portion of C-terminal protein, it is this region 
that the mutations affect in the cases of RS studied in this work. 
 
Figure 1.2. DVL1 gene and protein structure. 
The top panel shows the exon structure of DVL1, which has 15 exons (the 14th is the 
location of the mutation in the three cases discussed in this project). The panel is a cartoon 
showing DVL1 protein structure, the length of each region is approximately to scale. Note 
the elongated C-terminus after the DEP domain. This is the region affected by the 
frameshift mutations studied in this work. 
 
B P 
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1.5.3. DVL C-terminus 
The DVL C-terminus is one of the more variable parts of the DVL proteins, with 
DVL3 in particular showing a number of unique residues.73 Nevertheless the 
majority of the sequence is still conserved between paralogues (only ~25% of 
the DVL3 C-terminal is unique to DVL374). The DVL-C-terminal (in some of the 
work grouped with the DEP domain) contains: critical sites for regulating the 
phosphorylation of DVL;75 sites that regulate stability through interactions with 
ubiquitin ligases76,77,78 and a degrading enzyme;79 binding sites for the Src 
tyrosine kinases discussed above;72 a Frizzled binding domain;80  sequences 
involved in nuclear localisation;81 a binding site of a deubiquitinating enzyme;82  
and a region that interacts with ROR2.83 More detail on the C-terminal 
interacting proteins is found in the Discussion, in the context of the findings of 
this project.  
1.5.4. Dvl mouse knockouts 
There are three Dishevelleds in mammals and the overlapping but distinct roles 
of each Dvl (murine) have been elegantly shown in a series of mouse 
knockouts.84 Dvl1 null mice display no physical phenotype, however they do have 
some social abnormalities.25 50% of Dvl2 null mice die at birth and the 
remainder show severe defects in patterning. In particular these are cardiac, 
neural tube, and segmentation defects.85 Dvl3 null mice will rarely survive until 
adulthood and have a similar phenotype to the Dvl2 nulls, but also show cochlear 
defects with the abnormal alignment of hair cells.86 Demonstrating the 
overlapping roles, through a more severe phenotype, 100% of Dvl1/Dvl2 double 
knockouts have a completely open neural tube and exencephaly as well as 
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cochlear defects similar to those found in the Dvl3 nulls.87 Dvl1/Dvl3 double 
knockouts are embryonic lethal but without neural tube defects suggesting a 
distinct role for Dvl2 in this respect.86 Dvl2/Dvl3 nulls have never been observed, 
suggesting early lethality.86 Transgenes under the control of the native 
promoters of other Dvls can rescue the lethal phenotypes caused by knockouts. 
For example a Dvl1 transgene could rescue the lethality of Dvl3-/- but not that of 
Dvl2-/-, however a Dvl3 transgene was able to rescue the Dvl2 double knockout.84 
This again demonstrates the overlapping (and perhaps redundant) roles of the 
DVLs. 
In summary the following conclusions can be drawn from the mouse models: 
Dvls have both overlapping and distinct functions; Dvl1 knockout has the least 
impact upon phenotype; and no single or combination of Dvl knockouts led to an 
osteosclerotic or RS phenotype, as was observed in the human cases studied in 
this thesis. 
1.5.5. The distinct roles of Dvl paralogs in WNT/Ca2+ signalling 
In contrast to the apparent redundancy discussed above, a study in isolated 
mouse embryonic cells found that the knockdown of any of the Dvl paralogues 
repressed the WNT5A-Ca2+ response. Each Dvl did this to a similar degree 
despite the fact that Dvl1 and Dvl3 make up a substantially smaller part of the 
total DVL pool. It was also found that neither Dvl1 nor Dvl2 over-expression 
could rescue the Dvl3 knockdown induced reduction in Ca2+ response.73 The role 
of Ca2+ falls largely outside the scope of this project, and, while the results 
discussed here are themselves compelling they do not sit comfortably with the 
substantial overlap in function demonstrated in the whole organism mouse 
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work. Given the almost complete absence of phenotype in the Dvl1-/- mouse two 
explanations present themselves: either Ca2+/WNT signalling via Dvl1 is of 
relatively little systemic importance, or in the whole mouse there is some 
compensatory mechanism that rescues function (which was not accounted for in 
the cell culture-based assay).  
1.5.6. DVL in Human Disease 
Until this work DVL mutations have been large not associated with a WNT-
related phenotypes in humans. DVL2 and DVL3 are not, to our knowledge, 
associated with human disease (excepting the two DVL2 variants in two cases of 
neural tube defects,61 see section 1.4.5). Monosomy 1p36 Deletion Syndrome, a 
disorder characterised by dysmorphism and mental retardation may conceivably 
be contributed to by a haploinsufficiency of DVL1. DVL1 sits in the region deleted 
in this syndrome,88 but as do many another of other genes.89,90,91 Critically these 
individuals do not have RS or osteosclerosis, nor do individuals with other 
chromosomal deletions of the region containing DVL1.92 
1.6. Summary of literature  
RS is a diverse clinical entity, which is divided on the basis of inheritance 
patterns into dominant and recessive forms. The phenotypes of the milder 
dominant and more severe recessive forms overlap but are distinct – severe 
segmentation defects occur almost exclusively in the latter. RS can be caused by 
loss-of-function defects in ROR2 and WNT5A, which are genes involved in 
PCP/WNT signalling: a pathway primarily associated with skeletal patterning 
and convergent extension. DVL1, the focus of this project, is also a component of 
the PCP/WNT pathway, but, until this work, has not been associated with RS. The 
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three affected individuals discussed in this thesis have a phenotype that 
combines RS with osteosclerosis (RS-OS).  
It is the osteosclerotic aspect of this phenotype which is the focus of this thesis, it 
was preferentially studied over the RS component for three reasons. Firstly loss-
of-function mutations in PCP/WNT mediators are associated with RS and gain-
of-function mutations in canonical WNT mediators are linked to osteosclerosis. 
From a biochemical perspective gain-of-function mutations are more interesting 
than the simpler loss-of-function. Secondly it is the osteosclerosis that 
differentiates these individuals from other RS cases, thus this new feature was of 
more immediate interest. Thirdly there are practical constraints regarding the 
study of PCP/WNT signalling which are detailed in the Discussion. 
1.7. Aims of Study 
This project was initiated by the identification of two cases of a novel disorder, 
termed RS-OS (work in review at the American Journal of Human Genetics), which 
shared a common genetic observation: de novo frame shift mutations in the 3’ 
end of the gene DVL1. This project has two broad aims. The first is to clinically 
define this disorder and search for additional cases in the literature. The second 
aim was to characterise the functional implications of these mutations, initially 
investigating the transcription and translation of the mutant alleles and 
subsequently determining the impact on the canonical WNT signalling pathway 
through transient transfection-based TOPFlash assays.  
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2. CHAPTER TWO – CLINICAL ANALYSIS 
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2.1. Strategy 
RS, as discussed in the introduction, is a widely heterogeneous disorder. This 
section of the project aimed to clinically characterise this osteosclerotic subtype 
of RS (RS-OS). Given the shared genetic aetiology across these three cases, we 
hypothesise that features beyond just the osteosclerosis may define this subtype 
of RS. However, as RS itself is so heterogeneous, describing unique features to 
these cases is essentially impossible (excluding the osteosclerosis). Additionally 
it is plausible that some cases in the literature may in fact belong to the subtype 
RS-OS, since without detailed x-rays the osteosclerosis could easily be missed. As 
such this section attempts to draw out aspects that are rare in RS but relatively 
consistent across the individuals with RS-OS, perhaps indicating the features 
distinct to this subtype.  A number of cases are also drawn from the literature, 
while there is no way to test the genetics of these individuals the presence of 
osteosclerosis could well be an indication that they fit our subtype.  
Some of the research in this section was carried out during a Summer 
Studentship, however the majority of the work occurred during this BMedSc.  
2.2. Clinical Methods 
My supervisor  (Stephen Robertson) identified Case 1 during his clinical practice. 
Angeline Lai (a collaborator from KK Women’s and Children’s Hospital, 
Singapore) identified Case 2. Case 3 was originally published by Eijkenboom et 
al93 and identified by the distinct clinical features during my research into RS-OS. 
The information from Case 1 was gathered through clinical examination and 
interview (conducted by myself and Stephen Robertson), and studying hospital 
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records. For Case 2 we examined clinical images and radiographs sent to us and 
used the information from a clinical examination and hospital records provided 
by Angeline Lai. We were also able to gather additional information when we 
interviewed Case 2 and their family during a visit to New Zealand at the end of 
2014. Sue Craw (Department of Radiology, Dunedin Hospital) assisted our 
interpretation of the radiographic findings from Cases 1 and 2. Information from 
Case 3 was gained by correspondence with Henricus Kunst (Radboud University 
Medical Center, Nijmegen, the Netherlands) and directly from the paper 
published by Eijkenboom et al.93 I have carried out a review of the RS literature, 
and it is this that identified Case 3 and allowed the characterisation of this RS-OS 
subtype and the identification of the other possible earlier cases (Cases 4-6). 
2.3. Case 1 
This female was born at term to non-consanguineous parents aged 31 (maternal) 
and 42 (paternal). A bi-lobed and hypomobile tongue, hypoplastic uvula, short 
nose, and wide mouth were observed at birth. In the hands camptodactyly, 
clinodactyly, and brachydactyly were present. In childhood she developed 
chronic otitis media (which was treated twice with grommets) and recurrent 
chest infections. All primary teeth failed to exfoliate and had to be surgically 
extracted, after which she was found to be oligodontic with the agenesis of 12 
secondary teeth.  
At the age of 13 she was 147.8cm tall (-1.25 SD) and weighed 40kg (-0.7 SD) with 
a head circumference of 60cm (>+2 SD) She had marked hypertelorism 
(intercanthal distance 4cm, >+2 SD), wide and depressed nasal bridge, short 
nose, and excessive anterior lower facial height (see Figure 2.1 for phenotype). 
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Pectus carinatum was observed. Additional to the oligodontia there was marked 
gingival hypertrophy, moderate tooth crowding, and severe mesial rotation of 
the upper left incisor. 
 
Figure 2.1. Clinical appearance of Case 1. 
This figure is reproduced from the clinical paper in the appendix of this work (ref.  1), it 
shows Case 1 at 16 years of age. A and B, the distinctive facial appearance with 
hypertelorism, wide and depressed nasal bridge, and midface hypoplasia. C and D, the 
hands a feet showing the brachydactyly, clinodactyly, and camptodactyly.    
 
At 16 years old radiographs revealed a marked generalised osteosclerosis, 
particularly observable at the base of the skull. The frontal sinuses were 
hypoplastic, the long bones undertubulated, and the ulna bilaterally bowed. The 
distal phalanges of the hands and feet were hypoplastic and the distal phalanx of 
the great toe and thumb were bilaterally bifid (Figure 2.2). Aside from the 
osteosclerosis the vertebral axial skeletal morphology was unremarkable, 
showing no rib fusions or hemivertebrae. She had bilateral mixed hearing loss. 
Dual-energy X-ray absorptiometry (DXA) found an average bone density of 
1.584g/cm3 (Z-score, which is an age and sex matched standard deviation, +5.9), 
and the lumbar density was 1.960g/cm3 (Z-score +5.9). At 21 years her height 
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was 159.3cm (25th centile) and a DXA scan found a relative and absolute rise in 
bone density to such that her lumbar vertebral density was now 2.08g/cm3 (Z-
score +7.4). Notably, mesomelia was absent. There was no history of pathological 
fractures. 
 
Figure 2.2. Radiographic appearance of Case 1. 
This figure is reproduced from the clinical paper attached in the appendix (ref. 1). The 
images were taken at 16 years of age. A and B show the dramatic osteosclerosis of the 
cranial vault particularly clear in the base of the radiograph (A) and the hyperdensity and 
thickness of the bone in the coronal CT (B). C and D show the left hand and feet with 
osteosclerosis, brachydactyly, clinodactyly, camptodactyly as well as the bifid thumb and 
great toe. E-G, note the generalized osteosclerosis, lack of segmentation defects, and the 
undertubulation of the long bones in F. 
 
These features (no rib fusions, mesomelia, or hemivertebrae) and the lack of 
parental consanguinity support a diagnosis of dominant, rather than recessive, 
RS.9 The common features of dominant RS present in this case (compared to the 
review in ref. 9, over 50% occurrence in dominant RS was considered common) 
are: hypertelorism, midface hypoplasia, short nose, wide and depressed nasal 
bridge, macrocephaly, clinodactyly, and brachydactlyly.  
2.4. Case 2 
This male was born at 36 weeks gestation by elective Caesarean section to non-
consanguineous parents aged 28 (paternal) and 29 (maternal). Antenatal scans 
were normal until 6 months gestation when short limbs and increased skull size 
were noted. A cleft lip and palate, and umbilical herniation were corrected at 
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birth. Bilateral intra-abdominal testes were treated by left orchidectomy and 
right orchidopexy.  
He was diagnosed with recurrent otitis media in childhood and his primary teeth 
failed to exfoliate prompting their surgical removal at 11. At 9 years of age 
weight and height were both above the mean, and the head circumference was 
62.7cm +>2 SD). Hypertelorism, a broad nasal root, a flattened nasal tip, and 
narrow nares were evident. A short tongue, gingival hyperplasia, and tooth 
crowding were found on oral examination. Brachydactyly, broad thumbs, 
camptodactyly (Figure 2.3), along with bilateral flat feet were found. There was 
no history of pathological fractures. 
Radiographs showed widespread osteosclerosis most markedly in the base of the 
skull (Figure 2.3) and cortices of the long bones. The long bones were 
undertubulated. The distal phalanges of the hands and feet were hypoplastic and 
terminal phalanx of the thumb was bifid bilaterally. A DXA scan at 11 years of age 
showed an increased bone mineral density, with an average of 1.264g/cm3 (Z-
score +7.6). Notably some common features of RS (micropenis and mesomelia) 
were absent.  
As in Case 1 the inheritance (sporadic) and the features (no micropenis, 
hemivertebrae, mesomelia or rib fusions, and presence of umbilical herniation, 
which is exclusive to dominant RS9) indicate dominant RS. Common features of 
dominant RS in this case (same criteria as Case 1) are: brachydactyly, 
hypertelorism, macrocephaly, midface hypoplasia, and cryptorchidism.  
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Figure 2.3. Hands and skull of Case 2. 
This is a section of a figure from the American Journal of Human Genetics paper enclosed in 
the appendix (in review). It shows that hands of Case 2 with marked brachydactyly and 
camptodactyly (D) and a lateral radiograph of the skull revealing the osteosclerosis, most 
noticeable at the skull base (E). 
 
2.5. Case 3 
This case was initially documented by Eijkenboom et al.,93 and while our lab 
received DNA samples we have had limited additional clinical information. The 
relevant findings from the paper are summarised, although the clinical detail is 
sparser than that presented for Cases 1 and 2.  
This case was a 17-year-old female, born at full term in an uncomplicated non-
consanguineous pregnancy. Dysmorphic facial features, brachymesomelia, 
intestinal malrotation, umbilical herniation, and mild subvalvular stenosis of the 
pulmonary artery were noted at birth. Midface hypoplasia, hypertelorism, 
depressed nasal bridge, prominent forehead, long philtrum, a large and bifid 
tongue and dental malocclusions with the absence of 2 permanent lateral 
incisors were observed. She had a history of recurrent airway infections. She had 
bilateral mixed hearing loss. There was no reported history of pathological 
fractures. 
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Osteosclerosis (referred to as hyperostosis in the original paper from 
Eijkenboom et al.) was found in the skull and in particular the bones of the inner 
ear by CT scan, which the authors concluded provided an explanation for the 
hearing loss. To our knowledge no general X-rays were taken and no DXA scan 
was performed. 
Eijkenboom et al. concluded that the clinical diagnosis was one of dominant RS, 
due to the inheritance pattern (sporadic) and features (umbilical herniation and 
lack of segmentation defects). The classic facial features of RS and mesomelia are 
reported in this Case. 
2.6. Osteosclerosis previously in Robinow Syndrome 
As noted in the Introduction osteosclerosis in RS has been reported twice 
previous to this work, one in a father-to-son transmission12 and one sporadic 
case.13 Both of these have the features of dominant RS as well as the supporting 
inheritance pattern (vertical transmission and sporadic). In the sporadic case13 
the osteosclerosis was confined to the mastoids, but in the father-to-son 
transmission the father showed generalised osteosclerosis.12  
2.7. Robinow Syndrome with osteosclerosis 
It is our hypothesis that the three cases included in this thesis and the further 
three from the literature represent a distinct sub phenotype of dominant RS with 
osteosclerosis (RS-OS). As such five of these patients show osteosclerosis, 
measured either from DXA scans,1 radiographs,12,13 or CT scans.93 We 
hypothesise that the osteosclerosis is progressive. DXA scans of Case 1, first at 16 
then at 21 years-of-age, showed an increase in bone density. The sixth case, the 
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son of the osteosclerotic father described by Shprintzen et al,12 does not show 
osteosclerosis. This would be consistent with a progressive phenotype that was 
not visible at birth. The progressive nature of the osteosclerosis will only be 
confirmed by the on-going monitoring of these affected individuals. The 
following table summarises the notable clinical features of RS-OS. Findings that 
occur commonly in RS have been omitted (more than 50% prevalence from ref. 
9). It is worth noting, however, that the prevalence of some oral features is 
debated, a substantially smaller study, ref. 94, found that gingival hyperplasia, 
oligodontia, bifid tongue, cleft lip/palate, and gingival hyperplasia occurred more 
frequently in dominant RS than found in the larger cohort in ref. 9. This work 
uses the figures from the larger review, ref. 9, which are also included as a table 
in the Introduction.  
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Table 2.1. Clinical features of all reported cases of RS with osteosclerosis.  
Features that occur with a frequency of greater than >50% in dominant RS (from ref. 9) have been omitted.  
 
 Age at 
examination 
Bone Mineral Density Auditory 
Findings 
Oral Findings Herniation and 
other 
Source 
Case 1 - 
Female 
16 and 21 years General osteosclerosis on radiograph. 
DEXA scan revealed a lumbar bone density 
of 1.960g/cm3 (Z-score +5.9) at 16, and 
2.08g/cm3 (Z-score +7.4) at 21.  
Bilateral mixed 




All primary teeth failed to 
exfoliate. Absence of 12 
secondary teeth. Marked 
gingival hypertrophy, 
hypoplastic uvula, and a bi-
lobed tongue. 
None Ref. 1 
Case 2 – 
Male  
11 years Radiograph showed generalised 
osteosclerosis. DXA scan revealed a 
lumbar bone mineral density of 




All primary teeth failed to 
exfoliate. Gingival 
hyperplasia, and a left cleft 
lip and palate. 
Umbilical hernia at 
birth 
Ref. 1 
Case 3 – 
Female  
17 years Information on the general skeleton was 
not available, and those x-rays (if taken) 
were unattainable. However osteosclerosis 






Absence of two lateral 
incisors. 




stenosis of the 
pulmonary artery 
Ref. 93 
Case 4 – 
Male  
13 Slight general increase in bone density, 





Primary teeth failed to 
exfoliate. Oligodontia 
(missing 11 teeth), 
hypoplastic uvula, gingival 
hyperplasia 
Umbilical hernia Ref. 13 
Case 5 – 
Male  
23 General increase in bone density on 
radiographs, marked in the skull 
None Reported Bifid uvula and sub mucosal 
palate cleft, left side cleft lip 
 Ref. 12 
Case 6 – 
Male  
30 months None None Reported Bilateral cleft lip and palate Umbilical hernia Ref. 12 
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2.8. Summary of clinical research 
The work outlined in this section has established a clinically distinct entity: RS-
OS. This clinical definition, from Cases 1 and 2, was used to identify Case 3 from 
the literature, whose DNA was sequenced (see Chapter 4) and strengthened the 
evidence for the causative role of DVL1 mutations in this disorder. The clinical 
finding of RS-OS led us to hypothesise that these individuals have disrupted 
PCP/WNT signalling causing their RS and an over-activity in canonical WNT 
signalling leading to osteosclerosis (see Introduction). It is largely this 
hypothesised link to osteosclerosis that is assessed in the remainder of this 
thesis, for reasons indicated in the Introduction and Discussion. 
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3. CHAPTER THREE – LABORATORY 
MATERIALS AND METHODS
   34 
3.1. Outline 
This section contains the methods which were used multiple times throughout 
the lab-based part of this project. More detail on how each method was applied 
to a specific part of this work is included in the relevant section of the Results. 
3.2. Ethical Approval 
The Southern Health Research and Disability Ethics Committee approved this 
work, under the approval number 13/STH/56. 
3.3. Cell culture, RNA extraction, and cDNA synthesis 
3.3.1. Human fibroblast and C2C12 cell culture 
Human fibroblasts, extracted by dermal biopsy, from Case 1 and two unaffected 
controls were available in the laboratory. These cells were stored in media 
(described below) containing 5% DMSO (dimethyl sulfoxide) at -80oC. The 
mouse mesenchymal stem cell line C2C12 was used for the transfection 
experiments. Cultures were grown in DMEM (Gibco) supplemented with 10% 
foetal bovine serum (Moregate Biotech, FBSF) and 1% L-glutamine (Gibco, 
25030). They were maintained in 5% CO2 at 37oC. All cells were grown in 25mL 
or 75mL flasks and passaged at 80-90% confluence as assessed by inverted stage 
phase contrast microscopy.  
3.3.2. Human fibroblast RNA extraction and cDNA synthesis 
A confluent 25 mL flask of fibroblasts was trypsinised with 0.5mL of trypsin 
(Gibco) at 37oC for 3 min, diluted in phosphate buffered solution (PBS), then 
pelleted by centrifugation at 250 rcf (Eppendorf 5810R). The supernatant was 
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removed then the pellet processed using the NucleoSpin RNA kit (Macherey 
Nagel, 740902) according to the manufacturer’s protocol with 2-
mercaptoethanol added to the lysis buffer. The RNA was quantified using a 
NanoDrop®1000. 
The SuperScript®II kit (Invitrogen 18064) was used for cDNA synthesis. 0.5 μg 
of RNA was incubated with 0.5 μg of random hexamer primers in 11μL of MilliQ 
water for 5 min at 65oC. 4 μL of buffer, 4 μL of dNTPs (200 μM), and 1 μL of DTT 
(0.1 M) was added to the above reaction and incubated at 50oC for 1 h. A reverse 
transcriptase negative reaction was used to assess DNA contamination. The 
cDNA was diluted 1:4 in MilliQ water before PCR (polymerase chain reaction), 
either for mRNA sequencing or restriction digest (both described below). 
3.4. PCR and DNA manipulations 
3.4.1. Primer design 
Primers were designed using the NCBI Primer Design Tool and ordered from Life 
Technologies. Below is the table of primers used in this project. The DVL1 
genomic sequencing primers were designed by Tim Morgan and Heleen Rösken, 
and the CREB and DVL1-Mutagenesis primers by Phil Daniel (all from the 
Robertson Laboratory). 
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Table 3.1. Sequences of primers. 
 
3.4.2. PCR 
PCR was carried out using the KAPA Biosystems KAPA2G Robust kit (KK5004). 
0.5 U of Taq DNA Polymerase, 300 μM of each dNTP, and 0.5 μM of the forward 
and reverse oligonucleotide primers, made to a final volume of 10μL with the 5x 
Kapa Mg2+-containing buffer. Reactions were performed in a BioRad or MJ 
Research Dyad DNA engine. Unless otherwise stated programmes had an initial 
activation step of 94℃ for 2 min, followed by a variable number of cycles of 98℃ 
for 10 s denaturation, 60-72℃ annealing and then 72℃ extension. Programmes 
all finished with 2 min extension at 72℃. 
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3.4.3. Genomic and cDNA sequencing 
In order to confirm the synthesis of plasmids or investigate the presence of the 
mutation genomic DNA, PCR, and plasmid were prepared for sequencing with 
the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems). 4 μL of 
PCR product or 550 ng of plasmid and genomic DNA were added to 1 U Illustra 
Shrimp Alkaline Phosphatase (GE Healthcare, E70092X) and 5U of Exonuclease I 
(New England Biolabs, M0293), and the solution made up to 14 μL with MiliQ 
water. This was incubated at 80oC for 20 min. 3 μL of this reaction was added to 
5 nmol of primer, 1 μL of BigDye buffer and 1 μL of BigDye Enzyme mix and the 
solution made up to 10 μL with MilliQ water. The programme consisted of an 
initial denaturation step at 96oC for 1 min 15 s, followed by 24 cycles at 96oC for 
45 s, 50oC for 45 s, and 60oC for 3 min 30 s (manufacturer’s recommended 
conditions). After cycling 2 μL of 3M sodium acetate, 50 μL of 100% ethanol, and 
10 μL of MilliQ were added and the reaction mixed, which was centrifuged for 20 
min at 3000 rcf (Eppendorf 5415R) at room temperature. The supernatant was 
removed and pellet washed with 75 μL of 70% ethanol. The ethanol was then 
removed and the pellet left to air dry. The pellets were sent for analysis at 
Genetic Analysis Services at Otago University, who use an ABI 370xl DNA 
Analyser. 
The DVL1 reference transcript NM_004421.2 is used for the description of 
mutations within this thesis. 
3.4.4. DNA gels 
Electrophoretic DNA gels were used to visualise PCR products and cut plasmids. 
A 1.5-3% agarose gel was used appropriate to fragment size. 0.05% Ethidium 
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Bromide (Invitrogen) at 10 μL/40 mL gel or SYBR Green (Life Technologies 
S57567) used at 1/10,000 enabled visualisation with a UV FireReader (UVITEC 
Cambridge). 
For purification the fragments were visualised using the prep setting on the UV-
reader to identify the position of the desired band. Extraction was carried out 
with the QIAquick Gel extraction Kit (Qiagen 28704) following the 
manufacturer’s protocol. 
To quantify, the gels were visualised at sub-saturating exposures and either 
comparison to the DNA ladder or comparison directly between fragments was 
used to quantify either visually or using ImageJ. 
3.4.5 Restriction enzyme digest of DVL1 PCR product 
This was used to investigate the expression of the mtDVL1 transcript. PCR 
product containing the mutation site from Case 1 was produced by amplification 
for 35 cycles with the DVL1- Restriction Fragment (forward and reverse, Table 
3.1). 8μL of this product was then digested for 4 h at 60oC with 1 μL of the 
restriction enzyme BstN1 (New England Biolabs, R0168) in the PCR buffer with 
the addition of 1μL of NEB3.1 buffer (from kit). A restriction enzyme negative 
control was treated in an identical manner, with the exception that the BstN1 
was replaced with 1 μL of MilliQ water.  
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3.5. Synthesis of DVL1 expression constructs 
3.5.1. Construction of mutant DVL1 
The following process is also described in Figure 3.1. A wild-type clone of DVL1 in 
T7plus vector was available in the laboratory. Two mutagenic primer pairs: DVL1-
cDNASeq 44 (forward) and DVL1-Mutagenesis (reverse); and DVL1-Mutagenesis 
(forward) and DVL1-cDNASeq 2067 (reverse), were used to generate 5’ and 3’ DVL1 
fragments respectively (annealing temperature 65oC, 20 cycles). The template plasmid 
was digested from the 3’ reaction mixture using the restriction enzyme HindIII (New 
England Biolabs, R0104) in the 2.1 buffer (New England Biolabs) for 2 h, which left the 
3’ fragment intact. No suitable restriction enzyme was available for the 5’ fragment so 
gel purification (as previously described) was used to separate the template plasmid 
from the PCR fragment. The two fragments were quantified by gel electrophoresis. 4 μL 
of each solution was then denatured at 95oC for 2 min and then annealed for 5 min at 
60oC and 5 min at 72oC. 4 μL of this reaction was then used as a template with the full-
length DVL1 primers (DVL1-cDNASeq 44 (forward) and DVL1-cDNASeq 2067 
(reverse)) annealing at 62oC for 35 cycles. The product was gel purified (see Figure 
3.1). 
The mutated DVL1 was firstly polyA tailed and 5’-capped for expression, then cloned 
into the pcDNA 3.1 vector (Invitrogen, V795-20) with the TOPO®TA cloning kit 
according to the manufacture’s instructions (Life Technologies 450641) in a 10 μL 
reaction. 50 μL of chemically competent Escherichia coli (E. coli) DH5α were 
transformed with 5 μL of reaction mix and immediately plated onto agar plates with 
ampicillin selection (100 μg/mL). This was incubated overnight at 37oC and then the 
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colonies screened using a PCR reaction with the DVL1-cDNASeq 1373 (forward) and 
DVL1-cDNASeq 1634 (reverse) primers. Successful colonies were miniprepped, and 
Sanger sequencing used to confirm the fidelity of the transcript, then a maxiprep was 
used to generate large quantities of plasmid, quantified by nanodrop.  
3.5.2. Attachment EGFP tags to DVL1 constructs 
BamH1 and EcoR1 (New England Biolabs, R0136S and R0101S) in NEB buffer 2.1 for 1 
h were used to cut the DVL1 from the pcDNA 3.1 Vector and open a pcDNA3.1 based 
EGFP-tagged (enhanced green fluorescent protein) plasmid (Addgene, 13031). The 
accepting plasmid was CIP (Alkaline Phosphatase, Calf Intestinal, New England BioLabs, 
M0290) treated to prevent re-annealing and the DVL1 inserts gel purified from the 
untagged plasmid. Column purification with NucleoSpin Plasmid Kit (Macherey-Nagel 
740588) following manufacturer’s protocol was used to remove the restriction 
enzymes. Ligations were carried out overnight using a ~1:1 or 1:3 ratio of insert to cut 
vector, quantified by agrose gel (as previously described), with the T4 DNA ligase (New 
England Biolabs M0202).  
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Figure 3.1. DVL1 mutagenesis protocol. This shows the various steps of the DVL1 
mutagenesis as outlined in Section 3.5.1. The mutation is marked in red for clarity, the 
‘del’ primers refer to the mutagenesis primers in Table 3.1. 
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3.5.3 Cloning of DVL1 plasmids 
5 μL of the ligation reaction was then combined with chemically competent DH5α E. coli 
in L.B media (10 g/L tryptone, 5 g/L yeast extract, and 10 g/L NaCl at pH-7.0) and 
immediately plated if ampicillin selection was used (for untagged constructs, 100 
ng/mL ampicillin) or left for 1 h at 37oC if kanamycin selection was employed (for GFP-
tagged constructs, 30-60 ng/mL kanamycin). These were incubated at 37oC over night. 
Colonies were then selected and screened by PCR using appropriate primers before the 
presence of the construct was confirmed by sequencing plasmid DNA (described 
below). 
3.6. Production of DVL1 plasmids 
3.6.1. Small Plasmid Preparations 
Small DNA preparations were prepared from bacterial streaks grown overnight at 37oC. 
The Nucleospin Plasmid (Macherey-Nagel, 740588) kit was used to purify the plasmids 
after the bacteria were lysed in the lysis buffer (kit used according to the 
manufacturer’s MiniPrep protocol).  
3.6.2. Large Plasmid Preparations 
Large DNA preparations were made from 80 mL cultures that were grown overnight at 
37oC in a rotary incubator. The Nucleobond Xtra Midi Prep kit (Qiagen, 28106) was 
used according to the manufacturer’s MidiPrep instructions.  
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3.7. DVL1 protein analysis 
3.7.1. SDS-PAGE 
SDS-PAGE (sodium dodecyly sulfate-polyacrylamide gel electrophoresis) was used to 
separate proteins before Western blotting to enable their identification and 
quantification. All gels were 8% Bis-acrylamide with 0.1% SDS and were run until the 
marker reached the end of the gel at 200 V. An SDS containing loading buffer (130mM 
Tris-Cl pH-8.0, 20% glycerol 4.6% SDS, 2% DTT, 0.02% bromophenol blue) combined 
with cell lysis buffer (Promega, E1531) was used to lyse the cells and 20 μL of these 
lysates were directly run on the gel or lysates were stored at -20oC until needed. The 
running buffer consisted of 3 g/L Tris, 14.4 g/L glycine and 0.1% SDS. 
3.7.2. Transfer from polyacrylamide to nitrocellulose 
Transfers were carried out using the semidry TransBlot Turbo (Biorad), and 
transferred to 0.2μm nitrocellulose (BioRad, 162). Optimisation with ethanol and 
isopropanol supplementation of the transfer buffer (3 g/L Tris and 14.4 g/L glycine) 
was carried out, but it was concluded that the absence of alcohol led to the most 
reliable transfers. 9-10 layers of Whatman 3M filter paper were used in the transfer 
stack and the programme ran for 45 min at a maximum of 1.6 A or 25 V. 
3.7.3. Antibody incubations 
Membranes were blocked in 5% milk PBS at room temperature for 2 h. Incubations 
with all primary antibodies were conducted over night in 0.1% BSA in PBS-0.1% Tween 
at 4oC. Anti-DVL1 (Rabbit, Abgent AP12326c), anti-GFP (Rabbit, Life Technologies 
A6455), and anti-GAPDH (Mouse, Sigma G8795) were used at 1:1,000, and anti-α-
tubulin was at 1:250. The membranes were then washed for 3 x 10 min in PBS. HRP-
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tagged secondary antibodies were applied for 1 h at 1:5000 in 0.1% BSA, PBS-Tween 
0.1%. Alternatively IRDye® fluorescently tagged antibodies were applied for 1 h in 5% 
PBS-milk at 1:10,000.  The membranes were then washed again as above. The 
SuperSignal West Pico kit (Thermo Scientific, 34077) was used for chemiluminescence 
and films were exposed for times of between 5 sec and 30 min as appropriate. The 
Odyssey CLx (LiCor) was used to visualise fluorescence.  
3.8. Transient transfection assays 
3.8.1. Transfections 
To investigate the impact upon WNT signalling a number of luciferase-based 
transfection assays were carried out as described below. Either the wild-type DVL1 
(wtDVL1), the mutant DVL1 (mtDVL1) or a truncated form of DVL1 (shDVL1), which has 
a stop codon at the point of the mutation in Case 1 (i.e. it encodes a product similar to 
the mtDVL1, but does not have the new tail produced by the frameshift). All 
transfections were in C2C12 cells. These cells were split across 24-well plates, with 
40,000 cells per well in 0.5 mL of modified DMEM. The cells were immediately 
transfected with 80 ng of TOPFlash Reporter plasmid and 20 ng of β-galactosidase as a 
normalising control. Variable amounts of mtDVL1, shDVL1, and wtDVL1 vectors were 
transfected. Empty vector (pcDNA3.1 or) was used to ensure that the total DNA 
transfected (in ng) was consistent across an experiment. Cells were then incubated 
overnight before exposure to WNT3A containing media (available within the laboratory 
and produced from L-cells transfected with human WNT3A, a mouse enteric endocrine 
cell commonly used for this purpose, a technique first described in ref. 95) for 8 h, or 
simply incubated for 16-24 h. Subsequently the cells were lysed in 100 μL of firefly 
luciferase lysis buffer (Promega Kit, E1531). 
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3.8.2. Luciferase assays 
The Promega Luciferase Assay System (E1500) was used. Cells were lysed at room 
temperature in 100 μL of the provided lysis buffer (made up to 1x with MilliQ water). 
20 μL of the cell lysate per well was transferred to an opaque 96 well plate, which was 
kept on ice. The Synergy 2 Multi-Mode Reader (BioTek) pipetted 20 μL of luciferase 
reagent (from Promega Kit) per well and read the florescence for 3 s after a 1 s delay.  
3.8.3. β-galactasidase measurement 
After the luciferase reading the remaining lysis buffer was mixed 1:1 with a 2x β-
galactosidase reagent prepared according to manufacturer’s (Promega) instructions. 
This was incubated at 37oC until visible yellowing was present in all wells. An equal 
volume of 1 M Tris was added to stop the reaction and then 150 μL was pipetted to a 
transparent 96 well plate. The absorbance of this solution was read using Synergy 2 
Multi-Mode Reader (BioTek) at a wavelength of 440 nm. 
3.8.4. Normalising luciferase results 
All luciferase assays were performed with an internal duplication, using two separate 
wells. The average of these two luciferase intensities was divided by the average 
absorbance (β-galactosidase) of the wells to give a luciferase value normalised to the 
transfection efficiency. In order to allow comparison across repeats, given the 
substantial absolute variation in luciferase activity, each normalised luciferase value 
was divided by the average luciferase value of the plate to produce a “relativised” value. 
3.8.5. Statistics and graphs 
All statistics were carried out using “R” (with the “R Studio” interface, http://www.r-
project.org/). Data was log-transformed using the natural log to adjust for 
heterostochasticity when appropriate (in accordance with professional statistical 
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advice). One-way or two-way ANOVAs were used as appropriate, followed by post-hoc 
analysis using the Tukey Honest Significant Difference (HSD) test for the calculation of 
individual P-values. Graphs were drawn in Prism v6.0 (GraphPad).  
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4. CHAPTER FOUR –EXPRESSION OF 
ENDOGENOUS MUTANT DVL1 
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4.1. Strategy  
Previous to this project a combination of whole-exome sequencing and direct 
Sanger sequencing identified mutations in two of the three patients studied here. 
A third patient, identified by phenotypic information available in the literature, 
was studied using direct Sanger sequencing (results detailed in this section).  
We hypothesised that the similar mutations found in these three individuals 
were acting through a gain-of-function, which would require the expression of 
the mutant protein. Accordingly we investigated the presence of mRNA 
transcript in fibroblasts from Case 1, to exclude the nonsense mediated decay of 
the mutation-bearing transcript. Secondly we investigated the expression of 
mutant protein using Western blotting endogenous cell lysates from Case 1; the 
slight size differentiation between the mutant and wild type proteins predicted 
the presence of two bands. 
4.2. Identification of mutations in Case 1 and 2 
Before this work began a previous student in this laboratory, Heleen Rösken, 
used exome sequencing to identify the mutation in Case 1. At the time of this 
sequencing both Case 1 and 2 were known to the laboratory, and the absence of 
family history and consanguinity indicated that the phenotype was likely to be 
caused by de novo mutations. On this basis whole-exome sequencing using a 
parents-proband approach was taken to identify de novo variants in Case 1. Full 
methodological details of this approach is contained in the attached American 
Journal of Human Genetics paper, but two coding, rare, de novo variants in Case 1 
were validated by Sanger sequencing, one in DVL1 and the other in TNRC6A. The 
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DVL1 mutation is detailed shortly (Figure 4.2 and Table 4.1), but, in brief, it 
conferred a shift of the reading frame in the penultimate exon. TNRC6A encodes 
a component of the cytoplasmic ribonucleoprotein complex that regulates 
mRNA. The mutation in question (c.2753C>T, p.Pro918Leu, RefSeq 
NM_014494.2) was predicted by PolyPhen (a tool which predicts the deleterious 
nature of a variants on the basis of conservation and the physical properites of 
the amino acid changed) as likely to be benign.96 
The same approach was taken in Case 2, but whole-exome sequencing identified 
no mutations in DVL1 or TNRC6A. The sequencing coverage of the DVL1 region 
was, however, low. On this basis Heleen Rösken and Tim Morgan (also from this 
laboratory) Sanger sequenced the DVL1 exons of Case 2 and their parents 
(except for exon 1, for which functioning primers could not be designed). This 
revealed a very similar de novo mutation to Case 1, again producing a frameshift 
in the penultimate exon (Figure 4.2 and Table 4.1). 
4.3. Genomic Sanger sequencing of Case 3 
Our lab received samples from the Netherlands of Case 3 and her parents. We 
hypothesised that the mutation in this case was likely to be similar to those 
already identified in Cases 1 and 2. On this basis the penultimate and final exons 
of DVL1 were sequenced (Sanger chromatogram shown in Figure 4.1). A 
mutation was identified in the 3’ half of the 14th exon, denoted as 
c.1576_1583delinsG, which, as in the previous cases, leads to a −1 shift in the 
reading frame, in this case p.Pro526Alafs*121 at the protein level (see Figure 4.2 
for all three protein structures). 
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Figure 4.1. Sanger chromatogram from Case 3 and parents.  
These are the results from the genomic sequencing of Case 3 (top) and parents (bottom). 
The mutation is an eight base deletion with a single base insertion (1576_1583delinsG) 
leading to a −1 shift in the reading frame (protein product: Pro526Alafs*121). The blue 
lines indicate the section that is deleted in the case but present in the parents, the red G is 
the inserted base. Note the presence of a ‘double-trace’ in Case 3 showing the presence of 
two transcripts present: the wild type and the frameshifted mutant – this indicates 
heterozygosity.  
4.4. Summary of mutations in all three Cases 
The mutations in all three individuals are in the 14th exon of DVL1 and lead to a  
−1 reading frameshift. Each predicted mutant DVL1 protein is 23 residues 
shorter than wild type. All three have an identical 121-residue section of novel C-
terminal sequence. The mutations differ by only 21 amino acids at the N-
terminal aspect of the novel sequence (Table 4.1 and Figure 4.2). This new C-
terminal sequence contains a large number of basic residues, raising the 
predicted pI of the C-terminal section of the entire protein from 9.5 to 12.5.97  
Rare, similar, de novo mutations within the same region of DVL1 in all identified 
unrelated cases of RS-OS provide compelling evidence that these DVL1 mutations 
C G C C G A G G A C C C 
C G C T C G C C T A C C 
Case 3 
Parents 
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are causative of RS-OS. The mutations may be exerting their effect through either 
a loss- or gain-of-function. On the basis of homozygous mouse knockouts of 
Dvl125 and the phenotype of individuals with chromosomal deletions of the DVL1 
containing region,92 neither of which exhibit osteosclerosis or RS, we 
hypothesised that this mutation is acting through a gain-of-function rather than a 
loss-of-function. Driven by this hypothesis we investigated the presence of 
endogenous mutation-bearing mRNA transcript in cell lysates of Case 1. 
Table 4.1. Mutations across the three cases.  
Each mutation leads to the same reading frameshift and a novel C-terminal sequence. The 
last 121 C-terminal residues are identical across the Cases. The wtDVL1 length is included 




Figure 4.2. Cartoon of mutant and wtDVL1 proteins 
The three main regions of DVL1 are shown as is the predicted novel C-terminal sequence 
caused by the frameshift mutations (shown by the shaded box). Note the substantial 
length of new C-terminal sequence present in the mutant proteins. 
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4.5. mRNA analysis  
To investigate endogenous mRNA expression human fibroblasts extracted by 
dermal biopsy from Case 1 and an unrelated healthy control were cultured as 
described in Methods. RNA was extracted from a confluent 25mL flask and 
quantified by Nanodrop®-1000. cDNA was synthesised as described in Methods, 
and synthesis confirmed (contaminations was excluded with a reverse 
transcriptase negative control) with the reference CREB primers (see Appendix). 
4.5.1. Sanger sequencing of mRNA transcript 
Initially this cDNA was used for RT-PCR with the DVL1-cDNASeq 1477 (forward) 
and DVL1-cDANSeq 1793 (reverse) primers, this product was then sequenced. 
The sequenced trace revealed the presence of the frameshifted transcript in the 
mRNA population alongside the wild type DVL1 transcript (result not shown). 
This work is from my Summer Studentship, and it provides evidence that the 
mutant transcript persists and is not subject to nonsense mediated mRNA decay, 
which is consistent with the proposed gain-of-function of the mutant DVL1 allele. 
4.5.2. Restriction enzyme digest of mutant product.  
To confirm the above result we used a restriction digest with an enzyme that 
would specifically recognise, and cleave, the wild type DVL1 transcript while 
leaving the mutant intact. The DVL1-Restriction Fragment (forward) and DVL1-
Restriciton Fragment (reverse) primers amplified the region containing the 
mutation from the Case 1 and a healthy control cDNA. This was digested by the 
restriction enzyme BstN1 (as the described in Methods), and the fragments 
separated by agarose gel electrophoresis. Figure 4.3 shows the results of the 
digest. The PCR product runs at the expected molecular weight (~180bp). In 
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molecular weight (~120bp, the other restriction fragment has a molecular 
weight too low to be seen on this gel). Some of the fragment is however 
refractory to digestion and remains at the original weight. In contrast the 
identically treated control digests to completion, leaving only a band at the 
digested molecular weight. It is worth noting that accurate quantification is not 
possible from this data due to the likely mutant-wild type heteroduplex DNA that 
will be represented within the of the PCR products (these heteroduplices would 
be resistant to restriction digest). 
 
Figure 4.3. Restriction digest of Case 1 cDNA. 
The undigested sample reveals a band of the expected molecular weight (~120bp) in Case 
1 and in the healthy unrelated control. In Case 1 a fraction of the PCR product is refractory 
to digestion, whereas the digest proceeds to completion in the control, leaving only the 
band of the lower molecular weight (~60bp). 
 
4.6. Protein analysis 
Having confirmed the presence of mutation-bearing transcript we investigated 
the mutant DVL1 expression at the protein level. Using lysates from human 
fibroblasts from Case 1 and two controls endogenous protein expression was 
examined by Western blot with an anti-DVL1 antibody (Abgent, AP12326c) that 
has as its epitope the central portion of the protein (which is predicted to detect 
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both the mutant and wild type proteins). This revealed a band of the 
approximate molecular weight for DVL1, after SDS-PAGE using a small format 
gel, which was present in both the fibroblast cell lysates of the affected Case 1 
and two unrelated and unaffected controls (not shown, work conducted during 
my Summer Studentship). Initial optimisation was carried out using the small 
format gel however this was found to be insufficient to separate mutant from 
wild-type protein by molecular weight (not shown). Mathematical modelling 
based on the migration of the molecular weight markers suggested that a large 
format gel would allow the resolution of the smaller mutant protein from the 
wild type. However this technique, despite providing the predicted separation 
(confirmed by the migration of the molecular weight marker), also failed to 
provide a separation of the two bands (Figure 4.4). 
 
Figure 4.4. Western Blot of lysates with anti-DVL1 antibody.  
Western blot of lysates from Case1 fibroblasts and two healthy, unrelated controls. Note 
the apparent, faint, single band present across all three samples, this ran at the 
approximate molecular weight of DVL1 (~73kDa). Visualised with chemiluminescence. 
 
The isoelectric point calculator98 was used to estimate the impact on the overall 
charge of DVL1 from the mutant C-terminus. The novel C-terminus was 
predicted to have a dramatic effect on the overall charge, raising the predicted pI 
of the entire protein from ~7 to ~10. This calculation does not take into account 
post-translational modifications which can have a substantial impact on charge 
(e.g. phosphorylation) but it provides an indication that there may be a 
Case 1 Control 1 Control 2 
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divergence in the pIs of the mutant and wild type DVL1 proteins. We 
hypothesised that this divergence in charge could be exploited to allow the 
separation of mutant from wild type protein in a native gel.  On this basis a 
collaboration was undertaken with Dr. Alan Carne (University of Otago, 
Department of Biochemistry) who had the experience and resources to conduct 
2D gel electrophoresis, which initially separates proteins in a native gel on the 
basis of charge and subsequently, in the second dimension, by molecular weight 
with SDS-PAGE. A number of unsuccessful attempts were made using this 
technique. Western blotting with the anti-DVL1 antibody, following 1D SDS-
PAGE, produced a single band of the predicted molecular weight for DVL1 across 
all samples, as was previously found (Figure 4.4). However a sample of fresh 
culture media also showed the same band (Figure 4.5). This indicated that the 
commercial antibody was cross-reacting with a component of the media of the 
same approximate molecular weight as DVL1, rendering the detection of 
endogenous protein impossible with these components. 
 
Figure 4.5. Western blot with anti-DVL1 antibody showing cross-reactivity.  
The lysate from the control human fibroblast and fresh culture media both yielded a band 
running at the approximate molecular weight of DVL1. This indicates that the antibody is 
cross-reacting with a protein in the culture media of the same approximate weight of 
DVL1. This blot is visualised with chemiluminescence. 
4.7. Summary of mutant DVL1 expression 
All three Cases (including Case 3, who was identified in this project) show very 
similar de novo frameshift mutations, providing compelling evidence that these 
Control Media 
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DVL1 mutations are causative of RS-OS. The similarity between the mutations in 
the three cases supports the generalisation of experiments performed with 
endogenous cells from Case 1, or a construct bearing the mutation found in Case 
1 (mtDVL1), to the other two cases (from which we do not have access to live 
cells). Supporting the proposed gain-of-function in Case 1 it was found that the 
mutant allele was expressed at the mRNA level through cDNA sequencing and a 
restriction enzyme digest. Detection of the protein from endogenous lysates 
proved impossible due to a cross-reactivity of the antibody to a component of the 
culture media. However the persistence of the mRNA transcript makes the 
presence of the mutant DVL1 protein plausible. The expression of mutant 
protein is investigated in the following section using a transfected tagged-DVL1 
construct, which can be reliably detected by Western blot. 
   57 
5. CHAPTER FIVE– DVL1 CONSTRUCT 
SYNTHESIS AND EXPRESSION 
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5.1. Strategy 
In order to study the effect of the RS-associated DVL1 mutation expression 
constructs that could be transfected into WNT responsive cells (C2C12 cells) 
were required. Constructs were already available in the laboratory for the 
wtDVL1 and the shDVL1 (as described previously in Methods this is a truncated 
construct which terminates at the point of the mutation in Case 1, it is used to 
investigate the impact of the novel C-terminal sequence caused by the 
frameshift). However there was no construct available for the mtDVL1. Thus the 
first half of this section details the unexpectedly involved process of synthesising 
this mtDVL1 construct.  
In order for the mutant DVL1 to be acting through a gain-of-function the mutant 
protein must be expressed, and to assess this we required a detectable form of 
DVL1. The failure of the anti-DVL1 antibody (detailed in the previous chapter) 
meant that this detection necessitated the use of tagged constructs. Additionally 
the ability of DVL1 to form puncta (detailed in the Introduction, Discussion, and 
later in this chapter) is a requirement for canonical WNT signalling, which again 
has relevance to the proposed gain-of-function. A fluorescent tag would enable 
detection by Western blot and visualisation of the subcellular localisation of the 
mutant DVL1 by fluorescent microscopy. An EGFP-tag was chosen, as the 
laboratory possessed a robust anti-GFP antibody.  
5.2. Direct cloning of mutant DVL1 
Initially an attempt was made to clone the mtDVL1 directly from Case 1 cDNA. In 
order to facilitate the amplification of long sections of mRNA oligo-DT was used 
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as a primer in cDNA synthesis instead of random hexamers. The primers to the 
reference gene CREB (CREB-F and CREB-R) were used to confirm the cDNA 
synthesis (result not shown). A number of attempts were made to PCR the full 
length DVL1 using the DVL1-cDNASeq 44 (forward) and DVL1-cDNASeq 2067 
(reverse) primers, however these all failed. Attempts were made to optimise the 
PCR using a temperature gradient, the Kapa GC-rich buffer, and supplementation 
with betaine (which aids PCR by reducing GC secondary structures), however 
none of these were successful, yielding gels without bands (results not shown). 
Direct cloning was abandoned at this point, and a mutagenesis approach was 
taken, as described below.  
5.3. Mutagenesis of wtDVL1 plasmid 
The steps of the mutagenesis are described in the methods section. After the 
purification of the 3’ and 5’ fragments quantification by gel electrophoresis 
showed an equivalent amount of both fragments (Figure 5.1) so a 1:1 ratio was 
used in the annealing. PCR amplification of full length was successful (Figure 5.1) 
 
Figure 5.1. Intermediate results in the mutagenesis of the wtDVL1 plasmid.  
The left hand gel shows the presence of the 3’ and 5’ fragments of the mtDVL1 running at 
the predicted molecular weights (produced with the mutagenesis primers from wtDVL1 
plasmid), this gel was used to purify the fragments (as described in Methods). The right 
hand gel shows the successful PCR of the full length mtDVL1 from the annealed 3’ and 5’ 
fragments, this product was cloned. 
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The full-length mtDVL1 (shown on a gel in Figure 5.1) was ligated into the 
pcDNA3.1 plasmid as described in Chapter 3. 
The plasmid was cloned into chemically competent E. coli using the steps 
described in the methods section. 14 individual colonies were screened using the 
T7plus-F and the DVL1-2067R primers, which should selectively amplify only 
correctly orientated inserts. This PCR screen (in Figure 5.2) would allow the 
selection of colonies that were expressing the plasmid with the correctly 
oriented insert.  
 
Figure 5.2. PCR screen of DH5α colonies.  
The T7plus (forward) and DVL1-cDNASeq 2067 (reverse) primers were used to amplify 
the DNA extracted from the E. coli colonies. This pair of primers was predicted to only 
amplify plasmids with the correct orientation of the full-length mtDVL1 vector. Only 
colony 11 from this screen revealed a band of the approximately correct molecular weight 
of mtDVL1 (~2kb). 
 
The PCR screen revealed that colony 11 was a likely candidate (see Figure 5.2), 
and on this basis a maxiprep was performed, and the insert sequenced. Sanger 
sequencing showed that despite the selective PCR screen the insert was not in 
the correct orientation, perhaps due to contamination of the sample. A second 
PCR screen of an additional 14 colonies (numbered 15-28) was performed as 
above, and colony 21 chosen on the same principles discussed previously (result 
not shown). A small plasmid preparation was made (see Methods) and 
sequenced, revealing that the insert was correctly oriented. A larger preparation 
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was performed and Sanger sequencing confirmed the presence of the insert in 
the correct orientation, and this construct was used in all future work.  
5.4. EGFP-tag addition 
The newly synthesised mtDVL1 plasmids alongside the already available wtDVL1 
and shDVL1 plasmids were used as a source of the wtDVL1, mtDVL1, and shDVL1 
inserts. Both the plasmids containing inserts and the empty EGFP plasmid were 
digested with EcoR1 and BamH1 as described in the Methods section, column 
purified, and then gel purified from the gel shown in Figure 5.3, as described in 
Chapter 3. 
 
Figure 5.3. Restriction digestion of DVL1 inserts cloned into the EGFP vector.  
The right hand lane shows the open EGFP vector (note that it runs as a single band rather 
than a series of  bands as you would predict from a circular plasmid). The three left hand 
bands show the removal of the DVL1 inserts, note the substantially smaller length of the 
shDVL1, this is a truncated form of DVL1. 
 
The EGFP and DVL1 inserts were initially ligated for 2 h at room temperature 
with a 1:1 ratio of insert:vector as described in the Methods, but after a series of 
optimisations of the time and ratio was revised to an overnight digest with a 2:1 
ratio of insert:vector. 5μL of this reaction mixture was incubated in 4mL non-
selective LB media (described in Methods) with 100 μL of competent cells at 
37oC for periods ranging from 20 min - 2 h (30 min proved optimal) to allow the 
development of kanamycin resistance (the antibiotic resistance encoded in the 
   62 
EGFP plasmid), before the cultures were spun down and spread on kanamycin 
selective plates (as described in Methods). These plates were incubated over 
night at 37oC.  
Given the difficulties in using the PCR screen to select for colonies expressing the 
plasmid (the false positive discussed previously) an alternative method was 
used. Four colonies were selected from each construct and miniprepped. A digest 
with BamH1 and EcoR1 was then used to screen for the presence of the insert 
(results not shown). Colonies that expressed the insert containing plasmid were 
then MaxiPrepped and Sanger Sequencing confirmed the presence of the correct 
insert (results not shown). 
5.5. Expression pattern of EGFP-tagged constructs 
As detailed in the Introduction and Discussion wild-type DVLs have a distinctive 
punctate expression pattern33, and this pattern of expression is important to DVL 
function34 (see Discussion). The region of DVL responsible for this pattern, as 
stated previously (Introduction) is the DIX domain,37 which falls outside the 
region affected by the mutation. We therefore hypothesised that the mtDVL1 
would show a similar punctate expression pattern. To investigate this, EGFP-
tagged constructs were transfected into C2C12 cells at both 50 ng/well and 100 
ng/well and the cells viewed after 20 h. It was determined that the best images 
were found at 100 ng/well, Figure 5.4 shows representative results of three full 
technical repeats. 
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Figure 5.4. Fluorescent images of the EGFP-tagged DVL1 constructs.  
Note the similar punctate expression pattern between each EGFP-DVL1, which contrasts 
with the expression pattern of EGFP (included as a reference).  
 
All three constructs show a punctate expression pattern, with an apparently 
cytoplasmic distribution, which differs from the expression pattern of GFP 
(Figure 5.4). No apparent striking differences in subcellular distribution were 
noted between cells transfected with any of the DVL1 constructs.  
5.6. Western blot 
The level of protein expression of each construct is clearly an important 
question, especially given the inability to detect endogenous mutant DVL1 (see 
Chapter 3). As previously discussed we hypothesised that this mutation was 
acting through a gain-of-function, which also led us to hypothesis that the mutant 
protein was produced and stable, which was visually supported by the EGFP 
fluorescence detailed above. In order to assess the relative expression of each 
transfected DVL1 construct Western blotting was deployed after SDS-PAGE, as 
described in the Methods section. It was found that a single well yielded an 
insufficient amount of protein to detect (both with the anti-GFP antibody and 
anti-GAPDH). Thus four wells were combined in a total volume of 100 μL of SDS-
lysis buffer (as described in Methods). The blot was visualised by 
chemiluminescence. All three DVL1s expressed at relatively similar levels (more 
quantitation follows) compared to a GAPDH control (Figure 5.5). 
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Figure 5.5. Western Blot of transfected GFP-tagged DVL1 constructs.  
Note the slight difference in molecular weight between the wtDVL1 and shDVL1 (a 
difference of 21 amino acids, referred to as shortDVL1 on this figure) and the striking 
difference between the shDVL1 and the other two constructs. GAPDH is used as a loading 
control. This blot was visualised with chemiluminescence. 
5.7. Quantitative Western blot 
To quantify the protein level three repeat transfections (same method as 
previous section) were carried out and visualised using the Odyssey fluorescent 
detection system (LiCor) and appropriate antibodies. It was found that the 
previous control of GAPDH was not reliably detected on this system so an 
alternative control of α-tubulin was deployed. The Western blot is shown in 
Figure 5.6. The relative expression of each construct, normalised to α-tubulin, is 
as follows: wtDVL1 1.0±0.2 (SEM), mtDVL1 1.6±0.3, and shDVL1 2.0±0.2 (see 
Figure 5.6). A significant difference was found between the expression of the 
wtDVL1 and shDVL1 by one-way ANOVA followed by Tukey HSD tests (P < 0.05). 
No other significant differences were identified. Note the lower molecular weight 
protein in the mtDVL1 expression, this is considered in the Discussion but its 
exclusion from quantification did not significantly change the relative expression 
(mtDVL1 expression would be 1.2±0.2 if the second band is excluded). 
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Figure 5.6. Quantitative Western blot of DVL1 constructs. 
On the left is the Western blot that shows the relative protein level of the EGFP-tagged DVL1 constructs (~100kDa, red) across three independently 
performed transfections. The α-Tubulin is included as a loading control (~50kDa, green). On the right is a graphical representation of the relative 
protein levels (normalised to α-tubulin). The wtDVL1 level was 1.0±0.2 (SEM, indicated by error bars), the mtDVL1 was 1.6±0.3, and the shDVL1 was 
2.0±0.2. One-way ANOVA followed by Tukey HSD tests revealed a significant difference (P < 0.05) between the wtDVL1 and shDVL1 only (marked with * 
on the figure). Note the smaller molecular weight product in the mtDVL1 lane particularly obvious in experiments 1 and 3. This has been visualized in 
wtDVL1 expression on other Western blots (data not shown). For the quantitative analysis above the smaller product was included, if it is excluded no 
additional significant differences are revealed (the mtDVL1 then expresses at 1.2±0.2).  
* 
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5.8. Summary of transfected DVL1 expression 
The mutagenesis of the wild type DVL1 to produce a mtDVL1 (which corresponds 
to the mutation found in Case 1) was the first necessary step for the subsequent 
investigations. The addition of the EGFP-tags to each of the constructs enabled 
the investigation of both the subcellular distribution and protein expression. The 
similarity in subcellular distribution indicates that DVL1, in the absence of C-
terminal and in the presence of mutant C-terminal, will still form the 
supramolecular puncta in an apparently similar distribution to wild type DVL1. 
The quantitative Western blot data shows that there is no significant difference 
in protein level between the wtDVL1 and mtDVL1 expression but the amount of 
shDVL1 protein is significantly increased. Possible reasons for this increase are 
considered in the Discussion. Critically, however, the quantitative information 
indicates that the mtDVL1 is not degraded to a greater degree than the wtDVL1 
in these assays (if anything it may be more stable, even if the second product was 
removed from the calculations). This supports the hypothesis that the mutant 
transcript, which was present in the affected individuals (as shown in Chapter 4), 
is translated into a stable protein, which is likely to persist within the cells of the 
affected individuals. The next chapter addresses the biochemical impact of this 
mutant DVL1 protein on the canonical WNT signalling pathway. 
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6. CHAPTER SIX – DVL1’S IMPACT ON 
CANONICAL WNT SIGNALLING
   68 
6.1. Strategy 
As outlined in the Introduction it is the osteosclerotic aspect of the clinical 
phenotype that is of particular interest to this work. Osteosclerosis is a rare 
clinical finding, and the pattern of generalised osteosclerosis in these individuals 
is reminiscent of the LRP551 and SOST44 mutations (detailed in the Introduction). 
Both of these cause an over-activity in the canonical WNT pathway, which leads 
to an osteosclerotic phenotype.4,51 Given the identification of mutations in a WNT 
mediator, DVL1, as causative of RS-OS and the similarity to the bone phenotype 
seen in over-active WNT signalling it seems likely that these mutations are acting 
to increase canonical WNT signalling. 
This chapter aims to address the impact of mtDVL1 on canonical WNT signalling. 
We hypothesise that mtDVL1 will be more active in the canonical WNT pathway 
than wtDVL1. The TOPFlash-based transient transfection assays detailed in this 
chapter aim to investigate this hypothesis. Secondarily, by comparison to the 
truncated DVL1 (shDVL1), this chapter also investigates the functional impact of 
the novel C-terminal sequence caused by the frameshift mutations in the affected 
individuals. Given the presence of the identical, novel, C-terminal sequence (see 
Chapter 3) in all three individuals we hypothesise that the new C-terminal 
sequence has an impact on the function of the mtDVL1, which is distinct from the 
truncation of the wild type C-terminal sequence alone.  
The TOPFlash reporter assay is a well-validated readout of the canonical WNT 
signalling pathway. This reporter contains three T-Cell Factor (TCF) response 
elements, which, in response to canonical WNT stimulus drive the expression of 
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a firefly luciferase.99 The TOPFlash reporter is deployed in this section to 
measure canonical WNT activity. As well as the TOPFlash a PDX11 plasmid, 
which constitutively expresses a β-galactosidase enzyme, is also used. The β-
galactosidase causes a colour change in a β-galactosidase substrate, which is 
proportionate to the amount of enzyme. This second readout is used to adjust for 
differences in transfection efficiency between wells. The luciferase reading is 
divided by the β-galactosidase activity reading to generate a “normalised” 
result. Each normalised readout from a plate is the “relativized” by dividing by 
the average of the entire plate. Repeats can then be compared using this 
relativized reading, which adjusts for the substantial difference in absolute 
luciferase activity across identical repeats. As a whole this assay system acts as a 
robust readout of canonical WNT signalling in WNT responsive cells, such as the 
mouse C2C12 cells used in this chapter. 
6.2. Impact of the expression of DVL1 constructs on 
canonical WNT signalling 
Primarily we hypothesised that the mtDVL1 would be more active in the 
canonical WNT pathway than the wtDVL1, and, as a secondary comparison, that 
the mtDVL1 would behave differently to the shDVL1. To investigate the pattern 
of activity of all three DVL1 construct increasing levels of DNA levels, from 0.5 
ng/well to 32 ng/well, were transfected and the cells incubated for 18 hours. The 
cells were then lysed and the luciferase activity read. Results are reported as a 
fold increase over empty vector. The wtDVL1 construct caused an approximately 
linear increase in canonical WNT signalling with the addition of more plasmid, 
up to ~29-fold over that of the empty vector at maximum amount of DVL1 used 
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in the transfection (32 ng/well). The shDVL1 showed a similar pattern of 
activation but only reached a maximum of ~19-fold over the empty vector. 
Intriguingly the mtDVL1 showed a completely different pattern, raising the 
luciferase activity over that of the empty vector (~3.5-fold by 8 ng/well) but 
then showing no further increase with increasing levels of transfection. The 
results of three separate experiments are present in Figure 6.1. Error bars are 
standard error of the mean. Log transformed 2-Way ANOVA revealed a 
significant difference between the mtDVL1 activity and each other construct (P < 
0.00001). The difference between the wtDVL1 and the shDVL1 was not 
significant at (P > 0.5). Post-hoc Tukey HSD tests found a significant difference 
between the mtDVL1 and each other construct at 16 and 32ng/well. 
This result is inconsistent with our primary hypothesis: in this assay the mtDVL1 
was significantly less active in the canonical WNT signalling pathway than the 
wtDVL1. The mtDVL1 and shDVL1 did, however, behave in a different manner. 
This supports the hypothesised additional function of the novel C-terminal 
sequence – yet, as with the comparison to wtDVL1, the novel function observed 
in this assay is not an increased activation of canonical WNT signalling. 
   71 
 
Figure 6.1. Luciferase activity with increasing DVL1 transfection.  
Each DVL1 construct was transfected at 0.5 ng – 32 ng/well. The luciferase activity is 
reported as a fold increase over an empty vector control. Note the similarity between the 
wtDVL1 and shDVL1 activity (approximately linear increase in luciferase activity), and in 
contrast the failure of the mtDVL1, after an initial increase, to further increase luciferase 
activity. A log transformed 2-way ANOVA found a significant difference (P< 0.00001) 
between the mtDVL1 and the other two DVL1 constructs. Post-hoc Tukey HSD test found 
significant differences at 16 and 32 ng/well between the mtDVL1 and the other DVL1 
constructs (P < 0.01 = ** and P < 0.001 = ***). 
 
6.3. DVL1 constructs’ sensitivity to WNT stimulus 
In the previous experiment no additional WNT ligand was added to the media, 
and we hypothesised that the mtDVL1 may be more sensitive than wtDVL1 to 
WNT stimulus. To investigate this WNT3A (a well-established canonical WNT 
ligand) stimulus using L-cell conditioned media (see Methods) was assessed. The 
canonical activity of each DVL1 at a high level of expression is unlikely to be 
   72 
modelling an endogenous phenomenon, so the lowest level of expression where 
each DVL1 had a notable effect upon WNT signalling was chosen to investigate 
the response to WNT3A (4 ng/well – effect was judged from Figure 6.1). The 
C2C12 cells were transfected with the appropriate DVL1 construct then 
incubated overnight. WNT3A conditioned media was added at 5-15% (control L-
cell media was used to keep the volume constant across the wells), and the cells 
were incubated for 8 h. As seen in Figure 6.2 all cells respond to the increasing 
percentage of WNT3A conditioned media with increasing luciferase activity 
(including the empty vector control). Disproving the hypothesis of an increased 
sensitivity of the mtDVL1 to WNT ligand no significant differences were found 
between the DVL1 constructs in a 2-way ANOVA, with Tukey HSD post-hoc 
analysis. It is notable that, in contrast to the high level of expression, at this 
lower level of transfection the mtDVL1 has a similar effect on luciferase activity 
to the other DVL1 constructs. 
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Figure 6.2. DVL1 constructs’ impact on the C2C12 response to WNT3A. 
Results are reported as fold over wtDVL1 activity at 5% WNT3A conditioned media 
stimulus. These are the results from 4 independent experiments, error bars are SEM. An 
empty vector transfection is included as a control to demonstrate the C2C12 endogenous 
response to WNT3A stimulus. The differences visible between the DVL1 constructs were 
statistically insignificant (two-way ANOVA, Tukey HSD tests). 
 
6.4. Synergy between co-expressed mtDVL1 and wtDVL1 
Given that the affected individuals are heterozygous and the earlier work in 
fibroblasts from Case 1 indicated the presence of both mutant and wild type 
transcript (Figure 4.3) we hypothesised that the abberant function of the 
mtDVL1 may depend upon the presence of wtDVL1. To investigate this mtDVL1 
was co-expressed with wtDVL1 (the shDVL1 was again included to determine the 
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relevance of the novel C-terminal sequence found in the mutant but absent in the 
truncated form). The same, low, fixed amount of DVL1 construct was used as in 
the previous section (4 ng/well), however there was no additional WNT 
stimulus. Each DVL1 construct expressed alone was compared to a 1:1 ratio of 
wtDVL1 to mtDVL1 or shDVL1 (at the same total amount of DVL1 per well, e.g. 2 
ng of wtDVL1 and 2 ng of mtDVL1/well). C2C12 cells were transfected and 
incubated with the appropriate constructs for 24 h. Each DVL1 caused a 
comparable increase in WNT activity over the empty vector, similar to the effect 
observed in the presence of WNT ligand (Figure 6.2). The co-expression of 
sh/wtDVL1 at the same total amount of DVL1 caused a non-significant (P > 0.1) 
~1.6-fold rise in luciferase activity over that of the wtDVL1 alone. The 
mt/wtDVL1 co-expression led to an ~3-fold increase in the canonical WNT 
activity over the wtDVL1 alone, this was significantly different from each other 
construct (P < 0.01). The results of 5 independent experiments are displayed in 
full in Figure 6.3, relative luciferase activity is a fold of wtDVL1, error bars are 
the standard error of the mean, statistical analysis was with a one-way ANOVA 
followed by Tukey HSD post-hoc tests. 
This result supports the initial hypothesis of this chapter that the mtDVL1 
activated canonical WNT signalling. However this action requires the presence of 
wtDVL1. Additionally the significant difference between the mt/wtDVL1 and 
sh/wtDVL1 co-expressions supports the proposed additional function of the 
novel C-terminal sequence. 
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Figure 6.3. Synergy between mtDVL1 and wtDVL1. 
Each well was transfected with 4ng of construct (either an empty vector control, a single 
DVL1 construct, or a 1:1 ratio of mt or sh to wtDVL1) and luciferase activity was measured 
after a 24 h incubation. Results are presented as a fold over the wtDVL1. Error bars are 
SEM. A significant difference in a one-way ANOVA followed by Tukey HSD post-hoc tests 
was found between the mt/wtDVL1 co-expression and each other DVL1-transfected cells 
(P < 0.01, indicated by **). No other significant differences were found between the DVL1 
constructs, although the sh/wtDVL1 caused an ~1.6-fold increase over that of the wtDVL1 
this was not significant (P > 0.1). 
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6.5. DVL1 co-expression and sensitivity to WNT stimulus 
Finally, to further investigate this ‘synergy’, the response to WNT stimulus of the 
co-expressed DVL1 constructs (i.e. mt/wtDVL1 and sh/wtDVL1) was assessed. 
The method of WNT stimulus previously described was followed, using L-cell 
derived WNT3A conditioned media. The difference between the mt/wtDVL1 and 
the sh/wtDVL1 co-expressions was maintained, as was the increase in luciferase 
activity over wtDVL1 expression in the mt/wtDVL1 co-expression (Figure 6.4). 
Both co-expressed DVL1 conditions responded with a comparable linear increase 
with an increased amount of WNT3A conditioned media, which was similar to 
the pattern observed in the individual DVL1 constructs (Figure 6.2, the empty 
vector and wtDVL1 response from this figure have been included in Figure 6.4 
for comparison). A two-way ANOVA found a significant difference between the 
mt/wtDVL1 co-expression and each other condition (P < 0.01). The sh/wtDVL1 
construct did not, as observed without WNT stimulus (Figure 6.3), increase the 
luciferase activity significantly over that of wtDVL1 alone. 
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Figure 6.4. The co-expressed DVL1s and response to WNT stimulus.  
At a fixed amount of mt/wtDVL1, sh/wtDVL1, and wtDVL1 (4 ng/well) increasing amounts 
of WNT3A conditioned media was used to stimulate the C2C12 cells (5-15%). Results are 
displayed as a fold of wtDVL1 at 5%, with error bars as SEM. The significant increase (P < 
0.01 = **) in luciferase activity observed in mt/wtDVL1 over that of wtDVL1 and 
sh/wtDVL1 without WNT (Figure 6.3) expression was maintained. The pattern or 
response to WNT3A remained the same across all of the DVL1 conditions (but only 
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6.6. DVL1 impacts canonical WNT signalling independent of 
stimulus with WNT ligand 
An incidental finding in this research is that WNT3A stimulus appears to affect 
WNT signalling in a manner that is independent of DVL1 transfection (i.e. the 
canonical WNT stimulatory effects of WNT3A and DVL1 are mathematically 
independent of each other in these assays). Figure 6.5 shows the same data as in 
Figure 6.4 with the empty vector control (the empty vector is shown in Figure 
6.2 and Figure 6.4) subtracted from each of the transfections’ luciferase activity. 
This flattens the relationship (see Figure 6.5) between WNT3A stimulus and 
increasing luciferase activity. There is an initial increase in luciferase activity 
with the addition of exogenous DVL1 (across all DVL1 constructs) this increase 
does not, however, potentiate the response to WNT3A stimulus (the relationship 
between DVL1 transfection and WNT3A stimulus on canonical WNT signalling is 
additive not multiplicative). This statistical independence of the two variables 
(WNT3A stimulus and DVL1 transfection) would be consistent with some 
interesting biochemistry, which will be considered in the Discussion.  
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Figure 6.5. Effect of DVL1 on endogenous C2C12 WNT3A response.  
Results are expressed as fold of wtDVL1 at 5% and error bars are SEM. This data is the 
same as that shown in Figure 6.2 and Figure 6.4, however the empty vector result has been 
subtracted from each condition. This transformation flattens the relationship between 
luciferase activity and WNT3A stimulus, this indicates that the rise in luciferase activity 
with increasing WNT stimulus is due to the endogenous C2C12 response to WNT3A, and is 
not dependent upon the transfected exogenous DVL1. 
 
6.7. EGFP-tags do not disrupt DVL1 signalling 
In sections 5.5, 5.6, and 5.7 EGFP-tagged constructs were used to confirm the 
expression pattern and level of mtDVL1 and wtDVL1. This experiment confirms 
that there was no substantial alteration in WNT signalling function of DVL1 from 
the addition of the EGFP-tag. Figure 6.6 shows the results of three independent 
luciferase assays with the EGFP-tagged constructs at 100 ng/well (the amount 
used in sections 5.5, 5.6, and 5.7). There was no significant difference (one-way 
ANOVA, Tukey HSD tests, P > 0.5) between the EGFP tagged or untagged 
   80 
constructs with either the mtDVL1 or wtDVL1. The EGFP-tags caused no increase 
in the WNT stimulatory ability of the mtDVL1, and caused only a slight, non-
significant, decrease in the WNT activation from the wtDVL1. This supports the 
validity of using the EGFP-tag to investigate the expression pattern and level of 
the DVL1 constructs, as it does not appear to dramatically effect function. 
  
Figure 6.6. Impact of EGFP-tags on canonical WNT signalling. 
This shows the results of three independent experiments at 100 ng/well of EGFP-tagged 
(denoted as “GFP”) and untagged mutant and wild type DVL1 constructs. Results are 
presented as fold of the empty vector and error bars are SEM. No significant differences 
were found between the tagged and untagged DVL1 constructs (one-way ANOVA, Tukey 
HSD tests, both P-values > 0.5). 
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6.8. Summary of the impact of mtDVL1 on canonical WNT 
signalling 
The initial finding that at high levels of transfection mtDVL1 was less active in the 
canonical WNT pathway than either wtDVL1 or shDVL1 (Figure 6.1) was 
unexpected as the phenotype seen in these individuals supports a gain-of-
function increase in canonical WNT signalling (see Discussion and Introduction). 
The subsequent investigation into the sensitivity of each DVL1 construct to 
external WNT stimulus also indicated against our hypothesis of a gain-of-
function increase in canonical WNT signalling from the mtDVL1. The wtDVL1, 
mtDVL1, and shDVL1 when transfected all had a similar impact upon the C2C12’s 
response to WNT stimulus (Figure 6.2), a response that appears to be largely 
independent of the exogenous DVL1 (Figure 6.5). However when co-expressed 
with the wtDVL1 the mtDVL1 caused a substantial increase in canonical WNT 
activity (Figure 6.3). This result is particularly pertinent to the affected 
individuals as they are heterozygous for the mutations in DVL1 and thus co-
express mutant and wild type DVL1.  
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7.1. Robinow Syndrome phenotype 
Apart from the osteosclerosis there are a number of other features consistently 
shared by the three cases studied here. The most striking of these is the 
oligodontia, which, at the severity shown here, is rare.100 Oligodontia does occur 
in dominant RS without osteosclerosis, but in only about 10% of cases9 whereas 
it occurred here in all three individuals studied here and one of the older cases 
from the literature13 (Case 4, see Chapter 2). The role of canonical WNT in tooth 
agenesis is well established,101 and thus the dysregulation of canonical WNT 
signalling which is implied by the skeletal phenotype may also explain the dental 
findings. Additionally hearing loss is a recurring symptom in all three cases, most 
reporting mixed bilateral sensorineural and conductive hearing loss. The 
recurrent otitis media could well be due to the osteosclerosis causing the 
eustachian tube to become obstructed (eustachian tube atresia was found in 
Case 393), and in turn the conductive hearing loss will, in part, be due to the 
chronic otitis media. The sensorineural hearing loss may also be due to the 
osteosclerosis as it could compress the eighth cranial nerve (auditory) as it 
traverses the temporal bone and internal auditory canal. 
7.2. Osteosclerotic phenotype 
While there are a number of factors that cause osteosclerosis, the pattern of bone 
overgrowth in these individuals is similar to that found in the LRP5 gain-of-
function mutants, who have over active canonical WNT signalling.51 In particular 
the generalised thickening of bone without an apparent rise in fragility (no 
history of unusual fractures in these individuals) is a strong parallel to these 
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mutations. This phenotype, in the context of recurrent de novo mutations in a 
WNT mediator, provides compelling evidence that this osteosclerosis is 
mediated by an increase in canonical WNT signalling. 
7.3. Expression of mtDVL1 
It is unlikely that the mutations in DVL1 exert their effect through a simple loss-
of-function. As discussed, no mouse knockouts of any DVL orthologue show 
osteosclerosis,84 and of the three DVL null mice those lacking Dvl1 have the 
mildest phenotype with no dysmorphic features.25 and while the Dvl2 and 3 null 
mice have a more severe phenotype (see Introduction) none display an RS-like 
phenotype or osteosclerosis85,86. In addition the database of human 
chromosomal abnormalities, DECIPHER,92 catalogues no individuals who have 
deletions over the region containing DVL1 as having similar features to the cases 
presented here. In order to investigate this gain-of-function hypothesis the 
expression of mtDVL1 at the mRNA and protein level was investigated. 
7.3.1. Expression of mtDVL1 at the transcript level 
Nonsense mediated decay (NMD) commonly leads to the degradation of 
transcripts possessing premature nonsense mutations.102 We hypothesised that 
the transcripts with the DVL1 mutations discussed here would resist NMD as the 
frameshift mutations do not lead to a premature nonsense codon before the last 
exon: NMD identifies aberrant transcripts by recognizing the exon junction 
complexes, allowing it to identify premature termination sequences if they fall 
before the last exon (NMD is reviewed in ref. 102). Initially simply RT-PCR 
followed by Sanger sequencing was used to look for evidence that the transcripts 
generated from the mutant allele persisted. Accordingly a frameshifted trace was 
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found on the chromatogram indicating that the mutant allele was present. This 
was confirmed by restriction enzyme digest. The enzyme recognised a site in the 
DVL1 transcript that was destroyed by the mutation, thus the mutant allele was 
resistant to its action. cDNA generated from fibroblasts from Case 1 showed a 
mixed population of DVL1 transcripts, some of which were refractory to 
digestion, whereas a control digested to completion. It is not possible to be 
strictly quantitative from these results as the RT-PCR generated products form 
heteroduplices and any heteroduplex with the mutant site will resist the 
restriction digest. However, qualitatively, it is clear that there is a non-negligible 
amount of mtDVL1 mRNA and thus NMD was not degrading the mutant 
transcript. 
It is worth noting that individuals with RS-OS are heterozygous, having both a 
wild type and mutated DVL1 allele, the Sanger chromatogram and restriction 
digest detailed in Chapter 4 both confirmed that the mutant transcript was 
present alongside the wild type (the co-expression will be discussed later in this 
chapter). 
7.3.2. Protein expression of mtDVL1 
The original approach taken was to use endogenous lysate from the same 
population of cells from case 1 used to investigate the mRNA expression. As 
indicated in Chapter 4 there was a problem with a non-specific interaction of the 
commercial antibody. Unfortunately the cross-reactivity to a component of the 
cell culture media identified a band that was approximately the same molecular 
weight as DVL1 thus for some time this work proceeded under the assumption 
that DVL1 was being identified by Western blot. This led to the pursuit of a 2-D 
   86 
gel electrophoretic method in an effort to use the differing charge to separate 
mutant from wild type protein. When the inefficacy of the antibody was 
identified well-validated DVL1 antibodies were sought from the literature. 
Almost exclusively they were directed towards C-terminal epitopes (as this is the 
most variable part of the DVLs, thus the best to distinguish the isoforms), and 
these were clearly of no help for this work because the mtDVL1 protein lacks the 
native DVL1 C-terminal. 
7.3.3. DVL1 – differences in DVL1 protein levels  
Using the transfected EGFP-DVL1 constructs it was shown that there was no 
significant difference in protein levels between the wtDVL1 and mtDVL1. This 
was indicated initially by the chemiluminescent Western blot (Figure 5.5) and 
then confirmed by the more quantitative results from the Odyssey (Figure 5.6). It 
is worth noting that a significant difference in protein level was found between 
the wtDVL1 and the shDVL1 (shDVL1 was ~2-fold wtDVL1), this, coupled with 
the non-significant increase in mtDVL1 will be discussed shortly.  
There is a second product, which across the three experiments in Figure 5.6 
occurs exclusively in the mtDVL1 (the second lower molecular weight band). In 
other Western blots (data not shown) a similar, albeit fainter, product has been 
seen in wtDVL1 expression. This product is likely to be a C-terminal truncation, 
as clearly the N-terminal-EGFP-tag is still present (this is what the antibody 
detects). Further work would be required to better determine the nature of this 
product, but that is outside the scope of this thesis. As was presented in the 
results, if the second product is excluded from the quantification, the mtDVL1 
protein level is still not lower than the wtDVL1 (it is ~1.2-fold). Thus these 
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results, irrespective of the second lower molecular weight product, confirm that 
the mtDVL1 protein is present at a similar level to wtDVL1, which is consistent 
with the proposed gain-of-function hypothesis. 
7.3.4. Subtle regulation of DVL1 protein stability 
The assay system used, with high levels of expression of DVL1 (100 ng/well 
transfected) may have been unable to pick up the subtle differences in DVL1 
protein stability due to endogenous regulators (and this assay did detect an 
increase in the shDVL1 stability). There are four regulators of DVL stability that 
have binding sites that may be affected by the mutations: these are three 
ubiquitin ligases and a DVL degrading enzyme.  
A proline motif (525-528, PPAY), within the region affected by the mutation, is 
the likely or confirmed binding site for three ubiquitin ligases: NEDL1,76 ITCH,77 
and NEDD4L.78 All three of these in co-expression with DVL have been shown to 
lead to DVL degradation (the critical domain, PPXY, is conserved throughout the 
DVL proteins). This degradation by ITCH and NEDD4L has been shown to 
directly negatively regulate canonical WNT signalling.77,78 Negative regulation 
was not assessed for NEDL1.76 Another, non-ubiquitinating, DVL regulator is 
guanine nucleotide binding protein β 2 (Gβ2). This protein interacts with the 
DEP-C region of DVL (which includes the region altered by these mutations). In 
concert with its functional partner, Gγ2, this protein has both been shown to 
degrade DVL and through this degradation inhibit canonical WNT signalling.79  
The mtDVL1 and shDVL1 are likely to be refractory to degradation by some or all 
of these mediators and future work could investigate the effect that these DVL1-
interacting proteins have on the stability of mtDVL1 and shDVL1 through co-
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transfection. However simply an increase in stability, and thus amount, of 
mtDVL1 over the wtDVL1 is not sufficient to explain the osteosclerotic 
phenotype. The supraphysiological expression of the mtDVL1 did not lead to an 
increase in canonical WNT signalling (see Figure 6.1), thus simply an 
accumulation of this mutant product does not, alone, explain the bone 
phenotype. 
7.3.5. Subcellular localisation of mtDVL1 
In order to signal in the canonical pathway DVL forms dynamic multimeric 
polymers via its DIX domain, in contrast to the original claim that the polymers 
were associations with cytoplasmic vesicles.33 The ability to form these 
multimeric polymers was particularly relevant to the mtDVL1, as the polymers 
are required for canonical signalling, the formation of these puncta was required 
to support the hypothesised gain-of-function effect of these mutations.88 The 
mtDVL1 and shDVL1 both possess DIX domains so it was likely that they would 
still polymerise. This was confirmed by this work which showed that the 
subcellular localisation of mtDVL1 and shDVL1 is similar to that of the wtDVL1, 
when examined by light microscopy. 
7.4. Impact of DVL1 on canonical WNT signalling 
7.4.1. Relationship between DVL1 transfection and WNT signalling 
We found, as has been previously demonstrated,80; 82 that DVL1 will increase 
canonical WNT signalling upon transient transfection in the absence of 
additional WNT stimulus. The results in Figure 6.1 showing the reduced function 
of the shDVL1 (with a C-terminal truncation) also align well with the literature,80; 
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82 however, in our experiments statistical significance between the activity of the 
shDVL1 and wtDVL1 was not reached. The most surprising result from our 
experiment however, was that the mtDVL1 was markedly less active than either 
the wild type or truncated forms. Essentially, after an apparent initial rise the 
mutant DVL1 failed to increase signalling at all. The mtDVL1 reduced impact on 
canonical WNT signalling compared to the wtDVL1 is unexpected given the 
osteosclerotic phenotype in the affected individuals but sits comfortably with the 
previous studies that have detailed the impact of DVL1 C-terminal truncation.80; 
82 The difference between the mtDVL1 and the shDVL1, however, indicates that 
this novel sequence is acting in a way that is distinct from merely the absence of 
C-terminal. 
Initially it was suspected that this result indicated that the mtDVL1 construct 
was simply non-functional, plausibly because of some substantial misfolding 
impacting its expression (as occurs with ROR2 mutations in recessive RS19). 
However the previously discussed work, which showed the pattern of mtDVL1 
expression was similar to the wtDVL1 (Figure 5.4), and the work on protein 
stability (Figure 5.5 and Figure 5.6), indicated against this effect being mediated 
by the degradation or sequestration of the protein. It is also worth noting that 
the mutant protein does increase signalling above baseline, it just fails to 
increase this signalling with increasing expression, this will be discussed shortly. 
There are a number of possible DVL1 interactions that relate to the C-terminus 
and could explain our observations. These are discussed below. 
It has been shown by Jung et al. that the C-terminal contains a site critical for the 
binding of a deubiquitinating enzyme (Usp14).82 The mutation of just a few C-
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terminal residues dramatically reduced the ability of DVL1 to signal in the 
canonical WNT pathway. In addition the Src family of tyrosine kinases, which are 
important for activation of WNT signalling downstream of DVL, bind to the C-
terminal of DVL2 (broadly homologous to DVL1-C-terminal) alongside their SH-3 
binding domain in a more N-terminal region.72 A 2013 paper identified that the 
protein IQGAP1 will bind with the C-terminal of DVL1 (residues 476-671). A 
knockdown of IQGAP1 was found to reduce DVL1 nuclear localisation in 
response to WNT stimulus.81 The nuclear localisation of DVL is a necessary step 
in canonical WNT signalling.35  
The mtDVL1 lacks the residues (see Table 4.1 and Figure 4.2 for the affected 
regions of the mutant DVL1s across the Cases) for all three of these interactions, 
but so does the truncated form (shDVL1) Thus the above may well, to some 
degree, explain the observed reduced function of the mutant they do not explain 
the difference between mtDVL1 and shDVL1. 
Work from Tauriello et al. on DVL1-Fz interaction does provide a possible 
explanation.80 In this work, using a series of binding assays, it is shown that the 
wild type DVL1 interacts with the Fz using both the DEP domain and the C-
terminal region (last 16 residues). A truncated form of DVL1 shows far weaker 
Fz binding. This novel C-terminal sequence is highly basic; it is therefore 
plausible that this new section of protein negatively affects the ability of the 
DVL1 to bind to the Fz, either simply sterically or due to its significant positive 
charge. 
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7.4.2. High levels of DVL1 transfection 
There is some evidence from this project that very high levels of DVL1 
expression may lead to a decline in canonical WNT activation. In the experiment 
investigating the impact of the EGFP tag (Figure 6.6) the wtDVL1, at 100 ng/well) 
only led to an ~8-fold increase over the empty vector, whereas at 32 ng/well an 
~29-fold increase was observed (Figure 6.1). Additionally the mtDVL1 at 100 
ng/well was less active (~0.66-fold) than the empty vector (Figure 6.6), in 
contrast to its ~3.5-fold increase at 8 ng/well in Figure 6.1. This is only a 
preliminary indication, and further experimentation would be needed to confirm 
that, at high levels of DVL1 transfection, canonical WNT activation declines. This 
finding is of little currently apparent biological relevance, and peripheral to the 
aims of this thesis, but it may become relevant in future work. 
7.4.3. Sensitivity to WNT stimulus and the WNT3A independence of 
DVL1 signalling 
The substantial increase seen in Figure 6.1 with wtDVL1 over-expression (and to 
a lesser extent with the shDVL1) is unlikely to represent a physiological property 
of DVL1, and this effect may well cloud other impacts of the mtDVL1 which are 
not simply mediated by the high expression level. Thus all future experiments 
focused at the lower level of DVL1 expression, 4 ng/well, a level at which the 
impact of DVL1 could still be observed over an empty vector.  
Firstly a difference between the wtDVL1 and the mtDVL1 or shDVL1’s sensitivity 
to WNT stimulus was investigated, and no difference was found (Figure 6.2). 
Interestingly it was observed that the impact of the DVL1 transfection on WNT 
signalling and the impact of WNT3A seemed to be mathematically independent 
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of each other. As more WNT3A conditioned media was added there was an 
increase in the canonical WNT activity in the cells transfected with DVL1 
constructs and the cells transfected with the empty vector (Figure 6.2 and Figure 
6.4). While the cells transfected with DVL1 showed a larger response to WNT3A 
stimulation than the empty vector cells in an absolute sense the rate of increase 
was the same in the cells with and without transfected DVL1 (Figure 6.5).  
As stated in the results this is an example of statistical independence, i.e. the 
DVL1 transfection does not, at this level, change the response to WNT3A 
stimulus. It was suspected that DVL1, as a component of the canonical WNT 
cascade, would potentiate the response to WNT3A stimulus but this did not 
occur. This implies that the DVL1 transfection is increasing canonical WNT 
activity in a WNT-ligand independent manner – i.e. the DVL1 increases the 
activity in canonical WNT pathway to the same degree regardless of the amount 
of extracellular WNT-ligand. It is worth noting that the C2C12 cells will express 
endogenous Dvl1 (they are a mouse cell line) and that the DMEM that the cells 
are cultured in (see Methods) is likely to contain WNT ligand, thus more work 
would be required to fully analyse this relationship. However the ability of DVL1 
to signal without WNT-ligand (which would be consistent with the above result) 
is an interesting hypothesis, which could be investigated in future work. 
7.4.4. Synergy when mtDVL1 and wtDVL1 are co-expressed 
When the mtDVL1 allele is expressed in trans (as it is in these heterozygous 
cases) with the wtDVL1 allele it has quite a dramatic effect on canonical WNT 
signalling (at 4 ng total DVL1/well) where it raises the activity three fold over 
that of wtDVL1 expressed alone (Figure 6.3). This rise in activity is maintained in 
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the presence of WNT3A stimulation (Figure 6.4). This may well explain the initial 
rise observed when mtDVL1 was transfected at low levels into C2C12 cells 
(Figure 6.1), this could result from a synergy with the endogenously expressed 
mouse Dvl1. A possible explanation of this interaction lies in DVL1 
phosphorylation. 
DVLs are phosphorylated in response to both canonical and non-canonical WNT 
stimulus.103 In particular Casein Kinases-1 (CK1) ϵ has proved to be an important 
mediator of DVL phosphorylation.70,75 Phosphorylation leads to an inactive form 
of DVL as shown by its inability to self-associate to form puncta.70,75 Puncta are 
known to be critical to the ability of DVL to signal in the canonical pathway.34 
Bernatik et al.70 found that CK1ϵ over-expression would phosphorylate wild type 
and C-terminal truncated DVL (DVL-ΔC – the construct was produced from a 
His502* mutant, which is very similar to our shDVL1’s Trp507* mutation) to the 
same degree. However the C-terminal deleted DVL remained self-associated in 
puncta after CK1ϵ addition, in contrast to the wild type DVL which dispersed in 
response to CK1ϵ. A subsequent paper75 found that if CK1ϵ was only present at 
endogenous levels (rather than the excess used by Bernatik et al.) it would not 
phosphorylate a DVL that lacked three critical C-terminal Ser and Thr residues.75 
These residues are conserved across the DVLs but absent from our mutants (in 
DVL1 they are Ser553, Thr554, and Ser556). This led to the conclusion that the 
effect observed by Bernatik et al. was likely due to over-expression of CK1ϵ, 
which was consistent with initial finding from Bernatik et al. that the DVL-ΔC 
would not pull down endogenous CK1ϵ.  
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Thus the CK1ϵ phosphorylation of DVL is a negative feedback on DVL function in 
the canonical WNT pathway. Either the CK1ϵ phosphorylation requires C-
terminal residues which are not present in the mutant,75 or the mechanism by 
which the phosphorylated DVL inhibits canonical signalling depends upon the C-
terminal itself.70 It is therefore plausible that the mutant resists this negative 
feedback. In particular the persistence of the mutant in an unphosphorylated 
state may allow it to stabilise the DVL1 puncta that are necessary for canonical 
signalling even though it seems to be inactive in the canonical WNT signalling 
pathway itself (Figure 6.1). There is some additional supporting evidence for this 
from the literature. Using a DVL2 construct that was mutated at these three key 
phosphorylated residues (but otherwise possessed a normal C-terminal) 
Gonzalez-Sancho et al.75 found that the canonical WNT activity of their mutant 
was identical to wild type DVL2 activity, except at the low levels of transfection 
where it was found that the “unphosphorylatable” construct was more active 
than wtDVL2. The work in this thesis indicates that this may have been due to an 
interaction with endogenous DVL, and that they may have found the same 
‘synergy’ we observed (note that their construct possessed an otherwise normal 
C-terminal, hence it still functioned in the canonical pathway at high levels of 
expression). 
This model of phosphorylation does not however completely explain the 
observation as it does not account for the difference between the mtDVL1 and 
shDVL1 when co-transfected with the wtDVL1. The sh/wtDVL1 transfection was 
not significantly different from the wtDVL1 alone, however it is worth noting that 
the P-value in the absence of WNT3A stimulation was ~0.15 so perhaps there is 
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a difference here that this work lacked the power to detect. That aside there is a 
difference between how the mtDVL1 and shDVL1 proteins behave in the 
presence of wtDVL1. Clearly the novel sequence has some new function, but as of 
yet there is no apparent explanation. It seems to be no coincidence that all three 
individuals not only lack the wild type DVL1 C-terminus in their mutant DVL1 
but also have the same novel sequence. 
7.5. Mutant DVL1 in PCP/WNT signalling 
As is discussed the DVLs are important canonical and non-canonical WNT 
mediators. The relationship between RS and non-canonical/PCP WNT signalling 
is robust, as previously discussed in the Introduction. During this project 
zebrafish were considered as a potential model of RS which would allow the 
investigation of the impact of the mutant DVL1. Zebrafish have previously been 
used to model PCP phenotypes,104 it is possible to observe shorter and broader 
somites, shortened A-P axis, and undulations in the notochord. For this thesis 
however this method proved unlikely to be applicable, notably because PCP 
signalling is gradient dependent and inhibition and activation of the pathway can 
yield the same phenotype43 (as considered in the Introduction). In a practical 
sense this meant that injection of both normal human DVL1 RNA and the 
mutation-bearing DVL1 RNA would disrupt PCP/WNT (this was done during the 
course of this study, but the results are preliminary, thus not included in this 
thesis). It was thought unlikely that there would be an easily identifiable 
difference between mutant and wild type DVL1 expression in the fish. In future 
use of in vivo targeted genetic mutation systems such as a CRISPR/Cas9 or 
TALENs could enable a study of this phenotype in an animal model.  
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The genetics provide very compelling evidence that the mutations described 
here are causative of RS in these patients. RS is a rare condition with only around 
100 cases in the literature in total, so the probability of finding such a similar 
mutation in three unrelated patients with RS, if it were not causative, is 
minuscule. 
This thesis has provided good evidence that in the canonical/β-catenin pathway 
the mtDVL1 is a gain-of-function (expression data from  
Figure 4.3, Figure 4.4 and Figure 4.5 and the activating interaction with wtDVL1 
in Figure 6.3 and Figure 6.4) and the same may be true with the impact on the 
PCP/WNT. This is in contrast to our hypothesis at the outset of this project that 
the impact upon the PCP/WNT pathway was likely to be a loss-of-function, in 
line with the demonstrated loss-of-function mutations in WNT5A20 and ROR214; 
15which are known to cause RS (see Introduction).  
Further research identified that the mouse knockout of Dvl1 which no physical 
phenotype,25 and, given the conservation of DVL1 across species,66 it is likely that 
these mice provide a good model for human loss-of-function. Additionally the 
database of chromosomal abnormalities, DECIPHER, does not identify RS in 
patients who lack a copy of DVL1. Therefore a simple loss-of-function is unlikely 
to explain the RS in these patients, and, perhaps the action of the mutant DVL1 
may be better considered as a disruption of PCP/WNT signalling (as considered 
in the Introduction). There are a number of important PCP/WNT mediators that 
interact with the C-terminal of DVL in particular PRICKLE1 and ROR2, which are 
discussed below. These both provide hypothetical mechanisms which could 
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explain this likely PCP/WNT defect, but future laboratory work is now required 
to further study the RS phenotype in these patients. 
7.5.1. Mutant DVL1-PRICKLE 
Prickle-DVL interaction is an interesting target as mice with null and 
hypomorphic Prickle1 alleles phenocopy human RS,23 and Drosophila prickle has 
been shown to interact with the DEP-C-terminal aspect of dsh (the protein 
sequence of which is strongly conserved in humans66).105 Of particular note it 
was found that the absence of prickle in mice led to the complete loss of Dvl2 
polarisation in chondrocytes (normally a critical part of PCP/WNT signalling) in 
the Robinow-like mice.23 One possible model is that the mtDVL1 fails to interact 
with PRICKLE1, thus does not polarise in response to PCP/WNT signalling, 
therefore disrupting the PCP gradient. 
7.5.2. Mutant DVL1-ROR2 
ROR2 is an integral part of the PCP pathway,30 and mutations in ROR2 can cause 
a Robinow Syndrome phenotype in humans and mice.15,14 It has been shown that 
mouse Ror2 (mouse) will interact with DVL3 (human) through the C-terminus, 
and that this interaction will inhibit canonical/β-catenin WNT activity (one of 
the known actions of the PCP pathway30).83 Thus another possible mechanism is 
that either the absence of C-terminal precludes ROR2 binding, or even that the 
new C-terminal interacts with ROR2 in some way to enhance PCP/WNT 
signalling. A consideration with this information is that this work was done with 
DVL3, which, while still heavily conserved, has the most atypical C-terminal of 
the DVLs,74 thus the possibility that the effect observed by the authors is unique 
to DVL3 cannot be dismissed. 
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7.6. Mutant DVL1 in Ca2+-dependent WNT signalling  
As detailed in the introduction there is another non-canonical WNT pathway that 
signals through changing the intracellular Ca2+ concentration. This pathway is 
sometimes considered a component of the PCP pathway (but is not in this thesis) 
as WNT5A also stimulates it44,45, but it is less well characterized than the PCP 
pathway (it is reviewed in ref. 46). As discussed in the Introduction DVL plays an 
important, and complex, role in this pathway by both inhibiting and activating 
Ca2+/WNT.47; 48 The impact of the mutation on Ca2+/WNT signalling has not been 
assessed largely because defects in Ca2+ dependent WNT signalling have not 
been associated with the clinical features in these individuals (namely RS and 
this pattern of osteosclerosis). This could be an area of future work. 
7.7. Conclusions 
 This work places mutations in DVL1 alongside ROR2 and WNT5A as causative of 
RS. These mutations cause a particular novel subtype of RS, that we have named 
RS-OS. The DVL1 mutations almost certainly act by affecting the PCP/WNT 
pathway (RS) and the canonical WNT pathway (osteosclerosis), and this thesis 
has elucidated the mechanism by which these mutations affect the latter. This 
work has shown that the mutant transcript persists in endogenous cells and that 
the protein is expressed, stable, and localises in a similar manner to wild type 
DVL1, supporting a gain-of-function. The subsequent work with the TOPFlash 
luciferase assays showed that these mutant alleles act in part through their novel 
C-terminal sequence and only increase canonical WNT signalling in concert with 
the wild type. The mechanism by which the mutant DVL1 effects canonical WNT 
signalling remains to be elucidated, but a gain-of-function mutation that relies 
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upon the presence of the wild type allele to act is, to the best of our knowledge, 
unique amongst Mendelian disorders. Given that these affected individuals are 
heterozygotes, co-expressing mutant and wild type DVL1 alleles, this work 
supports the hypothesis that the osteosclerotic phenotype is due to an increase 
in canonical WNT signalling. 
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RT-PCR of DVL1 from Case 1 (summer studentship work) 
Fig1, lanes 1-5 are with the APRT primers, and lanes 6-
10 are with the CREB primers. 1. positive control using 
cDNA previously synthesised in the lab, 2. negative 
control, 3. patient cDNA, 4. control one cDNA, 5. control 
two cDNA, 6-10 are repeats of the above. 
